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Abstract 
Angelman Syndrome (AS) is a neurodevelopmental disorder caused by loss of the 
maternal copy of UBE3A.  The paternal copy cannot compensate for the loss because it 
is subject to tissue-specific imprinting in the brain.  This imprinting is controlled by the 
reciprocal UBE3A antisense transcript (UBE3A-ATS) expressed only in the brain.  The 
goal of my thesis projects is to understand the underlying mechanism by which the 
UBE3A-ATS is regulated.  We found that UBE3A-ATS is expressed and UBE3A is 
imprinted in non-neurons from an individual with 187 kb deletion at the paternal allele.  
This suggests that expression of UBE3A-ATS does not require any neuronal factors, 
and the regulatory elements reside in the genomic region.  A minimal region consisted 
of the bipartite boundary element IPW and PWAR1 is identified using CRISPR/Cas9.  
Absence of this region leads to higher UBE3A-ATS expression and early UBE3A 
imprinting during neural differentiation.  SNRPN-PWAR1-UBE3A is in close proximity in 
3D, but this interaction largely remains the same during neural differentiation.  My thesis 
work not only demonstrates how UBE3A-ATS is regulated, but also provides evidence 
that interfering with UBE3A-ATS transcription reactivates UBE3A. 
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1. Chapter 1 
Chromosome 15q11-13 related disorders 
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General introduction 
Genomic imprinting is an epigenetic phenomenon by which genes are expressed 
in a parent-of-origin dependent manner.  This process occurs primarily in eutherian 
mammals, although it can also be observed in plants and metatherians.  The estimated 
number of imprinted genes varies from a conservative estimate of 100 genes (1) to 
more than 1,000 (2), depending on how such imprinted expression was ascertained and 
the criteria for determining whether a gene is imprinted (3). 
DNA cytosine methylation as well as specific active and repressive histone 
modifications are involved in mediating the allele-specific gene expression in genes 
regulated by genomic imprinting.  Most imprinted loci have an imprinting control region 
(ICR) that is an area of differential DNA methylation between the two parental alleles 
(1).  The ICR is typically methylated on the silent, repressed allele and unmethylated on 
the expressed, active allele.  Repressive histone modifications, such as trimethylation of 
histone H3 on lysine 9 (H3K9me3) and histone H3 lysine 79 (H3K79me3), often 
accompany DNA methylation on the repressed allele of the ICR (4).  Active histone 
modification such as di- and trimethylation of histone H3 on lysine 4 (H3K4me2 and 
me3), mono- and dimethylation of histone H3 lysine 79 (H3K79me1 and me2), and 
acetylation of histone H4 lysine 91 (H3K91Ac) often adorn the unmethylated allele at the 
ICR (4).  Altogether the ICR often controls the imprinted expression of all of the genes 
within the imprinted cluster, regardless of the parent of origin of their gene expression.  
Thus, the ICR harbors important epigenetic modifications that ultimately determine the 
allele-specific expression of several imprinted genes within a cluster. 
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Imprinted genes, which are expressed from a single parental allele, are 
functionally haploid in the organism.  Deletion or mutation of the single expressed allele 
leaves an organism null for the imprinted gene.  Several human neurogenetic disorders 
arise from the disruption of the expressed alleles of imprinted genes.  Prader-Willi and 
Angelman syndromes are caused by the loss of function from paternally and maternally 
inherited alleles of the chromosome 15q11-13 region, respectively (5).  Bechwith-
Wiedemann syndrome is caused by the loss of function from maternal chromosome 
11q15 (6).  Silver-Russell syndrome is caused by disruption of imprinted genes on 
chromosomes 7 (7) and 11 (6).  Pseudohypoparathyroidism (Albright’s hereditary 
osteodystrophy) and uniparental disomy 14 are also disorders caused by disruption of 
imprinted genes (8).  Complex genetic regulation underlies the imprinted genes in each 
of these disorders, making it difficult to generate cell culture or animal models. 
Human induced pluripotent stem cells (iPSCs) are becoming an attractive 
approach to modeling complex genetic disorders, such as those involving genomic 
imprinting (9).  The use of somatic cells derived from patients enables the genetic 
complexities to be captured in indefinitely self-renewing stem cells that are capable of 
differentiation into virtually any lineage.  Using iPSC technology, copy number variation 
and uniparental disomy that often lead to disorders involving genomic imprinting can be 
recapitulated in stem cells.  Our group has generated iPSCs from individuals with 
Prader-Willi syndrome, Angelman Syndrome, and Dup15q syndrome, which all involve 
copy number variation at an imprinted locus (10–12).  Epigenetic modifications are often 
erased and established during the reprogramming process involved in the establishment 
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of iPSC lines.  Extensive analysis of the relevant epigenetic modifications and gene 
expression is a stringent requirement for modeling disorders that involve genomic 
imprinting to ensure appropriate expression of imprinted genes. 
 
Imprinting disorders at chromosome 15q11-13 
The chromosome 15q11-13 contains genes that are essential for human brain 
development (5).  Subregion of chromosome 15q11-13 is subject to genomic imprinting, 
an epigenetic phenomenon in which genes are expressed in a parent-of-origin manner.  
As a result, some of the genes in the region are expressed in a mono-allelic fashion.  
When the active gene is absent, there is no compensation from the inactive counterpart.  
Angelman Syndrome (AS) and Prader-Willi Syndrome (PWS) are two imprinting 
disorders associated with this region.  More than 70% of these two disorders are caused 
by single allele deletion of the region (13).  AS is caused by deletion of the maternally-
inherited allele.  PWS is caused by deletion of the paternally-inherited allele.  The 
deletion usually takes place during meiosis mediated by repetitive sequences.  There 
are 5 break points (BP1-BP5) in this region that are prone to be misaligned due to their 
sequence repetitiveness.  The majority of AS and PWS cases is between BP2-BP3 
deletion, roughly 5 Mb.  The estimated prevalence of these two disorders is at the rate 
of 1 in 15,000 to 1 in 20,000 live births (13).  While progresses have been made to 
discover potential therapies, there is still no cure for these disorders at the moment. 
 
Imprinting at chromosome 15q11-13 
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Chromosome 15q11-13 displays two types of genomic imprinting.  The first type 
of imprinting is controlled by DNA methylation at the differentially methylated region 
(DMR).  Methylation occurs at the cytosine (C) on CpG islands.  The methylation status 
is usually reset during gametogenesis (14, 15).  Once the methylation is set up, the 
effect is global.  The expression from all the tissues will behave in a parent-of-origin 
specific manner.  The DMR in chromosome 15q11-13 is at the promoter of 
SNURF/SNRPN (16).  This is called Prader-Will Syndrome imprinting center (PWS-IC).  
The methylation only takes place on the maternal allele.  Due to the DNA methylation, 
many of the genes at the maternal allele are silenced.  The paternal PWS-IC is not 
methylated, leaving the paternal allele the only source of the RNAs and proteins in all 
tissues.  A map of the region is shown in Figure 1. 
The second type of imprinting is controlled by long non-coding RNA (lncRNA).  In 
contrast to the imprinting caused by DNA methylation at DMRs, which has the global 
effect in all tissues, this type of imprinting is tissue-specific.  Schematic illustrations are 
shown in Figure 2.  The promoter of SNURF/SNRPN gives rise to a lncRNA that hosts a 
protein coding RNA various small RNAs.  The transcription pattern of the lncRNA can 
be divided to two groups (proximal and distal).  The proximal cluster includes 
SNURF/SNRPN, SNORD107, SNORD64, SNORD108, SNORD109A, SNORD116, and 
IPW.  This transcript is expressed in all tissues.  The distal cluster includes SNORD115, 
SNORD109B, and UBE3A-ATS.  This transcript is expressed in excessive amount in 
neurons.  UBE3A-ATS is a reciprocal transcript of a protein-coding gene UBE3A, and it 
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is known that UBE3A-ATS is essential to silence UBE3A only in the brain (17).  Due to 
the tissue-specific expression of UBE3A-ATS, UBE3A is only silenced in the brain (18). 
 
Angelman Syndrome and Prader-Willi Syndrome 
AS was first described by Harry Angelman in 1965 (19).  It is a relative rare 
genetic disorder.  Several population-based studies have reported the estimated 
prevalence of AS to be around 1/10,000 to 1/20,000 (20–22).  Symptoms of AS 
individuals include severe intellectual disability, developmental delay, and speech 
impairment so they are solely dependent on extra care from the family.  The etiology of 
AS is known to be disruption of the maternal UBE3A (23, 24).  It is a single gene 
disorder.  Deletion of a 5-7 Mb maternally-inherited region containing UBE3A accounts 
for most of AS cases (~70%).  Mutation of the maternal UBE3A accounts for 20% of AS 
cases.  Imprinting defect at the PWS-IC and uniparental disomy together accounts for 
7% of AS cases (13).  While UBE3A expression is bi-allelic in other tissues, the 
maternal copy is the only actively transcribed allele in the brain (18, 25).  The paternal 
copy is silenced by the reciprocal UBE3A-ATS in the brain (17).  Targeting the UBE3A-
ATS to unsilence the paternal UBE3A showed promises as a cure for AS since these 
individuals still have the paternal copy present (26, 27).  Other therapeutic approaches 
have been focused on the function of UBE3A.  UBE3A encodes an E3 ubiquitin ligase 
that targets specific proteins for degradation through ubiquitin-proteasome system (28, 
29).  The function of UBE3A in the brain is still poorly understood.  Although studies 
have identified many UBE3A substrates, the findings only partially contributed to AS 
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pathology, perhaps due to irrelevant cell type chosen (30–37).  Even when a proper 
model system was used (38, 39), a target of UBE3A that contributes to AS pathology 
remains inconclusive (40). 
PWS was first described by Andrea Prader, Heinrich Willi, and Alexis Labhart in 
1956.  PWS is another genetic disorder with the similar prevalence around 1/10,000 to 
1/20,000 (13).  PWS is characterized with cognitive impairment, poor muscle tone, 
incomplete sexual development, obsessive eating behavior, and obesity (41).  Unlike 
AS, PWS is a contiguous gene disorder.  70% of PWS cases is due to 5-7 Mb deletion 
of the paternal allele.  25% of cases is caused by uniparental disomy, and 5% of cases 
is attributed to imprinting defect (13).  Since PWS is not a single gene disorder, no 
mutation cases have been identified.  Previously, the cause of PWS is thought to be due 
to loss of all paternally expressed genes.  Recent studies reported cases of PWS with 
atypical microdeletions (42–45).  The minimal overlapping region that includes 
SNORD116 cluster carrying multiple C/D box snoRNAs is likely to be the cause for 
PWS.  Although SNORD116 snoRNAs have potential gene targets due to the sequence 
complementarity (46), their real function remains poorly understood.  Similar to AS, the 
inactive maternal copy is intact in the individuals with PWS.  Reactivating the dormant 
imprinted SNORD116 cluster has the potential to be a therapy for PWS.  One study 
demonstrated that disruption of a complex that deposits H3K9 trimethylation (H3K9me3) 
on the maternal allele resulted in reactivation of SNORD116 (47). 
 
iPSCs for disease modeling 
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Genetically-manipulated AS mouse strains have helped us to recapitulate many 
phenotypes of AS patients, to reveal potential problems in neuronal morphology and 
synaptic plasticity of AS patients, and to monitor neuronal Ube3a imprinting during 
neuronal development (48).  They are, however, not ideal for studying mechanisms 
underlying the regulation of neuron-specific UBE3A-ATS in human.  Despite the fact 
that Ube3a/UBE3A is imprinted by the same mechanism between mouse and human, 
there is a subtle difference.  In human, the long non-coding SNURF/SNRPN 
transcription unit falls into two clusters, as mentioned earlier.  The proximal cluster of 
SNURF/SNRPN transcription unit is expressed ubiquitously in all tissues and 
transcription stops at IPW.  In mouse, however, the entire long non-coding 
SNURF/SNRPN transcription unit is brain-specific and there is no tissue-specific 
transcriptional stop at Ipw (49).  Therefore, it is necessary to use human tissue as a 
model system to study the underlying mechanism that governs the regulation of the 
neuron-specific distal cluster of the SNURF/SNRPN transcription unit. 
Taking advantage of the breakthrough discovery of human iPSCs in 2007 (50, 
51), we generated AS patient-derived iPSCs and their neuronal derivatives with proper 
characterizations (10).  We also generated iPSCs from patients with PWS.  With these 
two iPSC lines and their neuronal derivatives, we are able to study transcription and 
editing genomes in an allele-specific manner during neuronal development. 
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Figure 1. A map of chromosome 15q11-13 between break point (BP) 2 and 3.  
Open circles are differentially methylated regions (DMRs) that are not methylated.  
Close circles are methylated DMRs.  Blue boxes denote genes exclusively expressed 
from the paternal allele.  Red box denotes the gene exclusively expressed from the 
maternal allele.  Grey boxes are genes expressed bi-allelically.  Arrows indicate the 
direction of transcription. 
 
Pat 
Mat 
BP2 BP3 
UBE3A-ATS 
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Figure 2. Schematic illustrations of tissue-specific imprinting of UBE3A by 
UBE3A-ATS. In non-neurons, the proximal portion of SNURF/SNRPN lncRNA 
terminates at IPW.  In neurons, the transcript does not stop at IPW.  It transcribes 
further and gives rise to the distal portion of SNURF/SNRPN lncRNA, which includes 
UBE3A-ATS. 
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2. Chapter 2 
Imprinted expression of UBE3A in non-neuronal cells from a Prader-Willi 
syndrome patient with an atypical deletion 
 
Data presented in this chapter was published in the following paper 
 
Title: Imprinted expression of UBE3A in non-neuronal cells from a Prader-Willi 
syndrome patient with an atypical deletion 
Authors: Kristen Martins-Taylor1#, Jack S. Hsiao1#, Pin-Fang Chen1, Heather Glatt-
Deeley1, Adam J. de Smith2, 3, Alexandra I.F. Blakemore2, Marc Lalande1*, and Stormy 
J. Chamberlain1* 
1Department of Genetics and Developmental Biology, University of Connecticut Health 
Center, Farmington, CT, USA. 
2Section of Genomic Medicine, Imperial College London, Hammersmith Hospital 
Campus, Du Cane Road, London UK. 
3 Present address: Department of Epidemiology and Biostatistics, UCSF School of 
Medicine, San Francisco, CA, USA 
# equal contributors 
 
My contribution: Schematic illustrations of chromosome 15q11-13, RNA FISH, 
manuscript writing 
 
Permission to reuse the content was granted by Oxford University Press 
License number: 3942561058197 
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Abstract 
Prader-Willi syndrome (PWS) and Angelman syndrome (AS) are two 
neurodevelopmental disorders most often caused by deletions of the same region of 
paternally-inherited and maternally-inherited human chromosome 15q, respectively.   
AS is a single gene disorder, caused by the loss of function of the ubiquitin ligase E3A 
(UBE3A) gene, while PWS is still considered a contiguous gene disorder.  Rare 
individuals with PWS who carry atypical microdeletions on chromosome 15q have 
narrowed the critical region for this disorder to a 108 kb region that includes the 
SNORD116 snoRNA cluster and the Imprinted in Prader-Willi (IPW) non-coding RNA.   
Here we report the derivation of induced pluripotent stem cells (iPSCs) from a PWS 
patient with an atypical microdeletion that spans the PWS critical region.  We show that 
these iPSCs express brain-specific portions of the transcripts driven by the PWS 
imprinting center, including the UBE3A antisense transcript (UBE3A-ATS).  
Furthermore, UBE3A expression is imprinted in most of these iPSCs.  These data 
suggest that UBE3A imprinting in neurons only requires UBE3A-ATS expression, and 
not other neuron-specific factors.  These data also suggest that a boundary element 
lying within the PWS critical region prevents UBE3A-ATS expression in non-neural 
tissues. 
 
Introduction 
Angelman syndrome (AS) and Prader-Willi syndrome (PWS) are 
neurodevelopmental disorders that are most commonly caused by large deletions of 
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human chromosome 15q11-q13 (52).  Individuals with AS suffer from cognitive 
impairment, absent speech, seizures, ataxic gait, and a happy demeanor, while 
individuals with PWS initially present with hypotonia and failure-to-thrive (53).  PWS 
individuals then go through a phase of normal growth before progressing to a period of 
above-normal weight gain, and finally, a period of intense food seeking behavior and 
hyperphagia (54).  PWS leads to morbid obesity without diet, exercise, and often growth 
hormone intervention.  Individuals with PWS also suffer mild cognitive impairment, short 
stature, and behavioral issues including obsessive-compulsive disorder (41).  While the 
two disorders are very different from one another, they can result from exactly the same 
deletion, but the deletion differs in its parent-of-origin.  AS is caused by deletions of 
maternal chromosome 15q11-q13 and PWS is caused by the same deletion that occurs 
on the paternally inherited allele (52). 
The parent-of-origin specific effects of chromosome 15q11-q13 deletions occur 
due to the regulation of the locus by genomic imprinting.  A map of this region is shown 
in Figure 1.  The imprinting control region is a differentially methylated region 
encompassing the promoter and first exon of SNURF-SNRPN.  It is methylated on the 
paternal allele and unmethylated on the maternal allele (55, 56).  Several genes are 
expressed exclusively from the paternally-inherited allele, including MKRN3 (57), 
MAGEL2 (58), NDN (59), NPAP1 (60), SNURF-SNRPN (61, 62), SNORD107 (63), 
SNORD64 (49), SNORD108 (63), SNORD109A (63), SNORD116 (49), IPW (64), 
SNORD115 (49), SNORD109B (63), and UBE3A-ATS (17).  Several paternally 
expressed genes, including the SNORD genes, IPW, and UBE3A-ATS are non-coding 
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RNAs (ncRNAs) driven from the SNURF-SNRPN promoter (63).  In humans, 
SNORD107, SNORD64, SNORD108, SNORD109A, SNORD116, and IPW are 
expressed broadly across several tissues, but SNORD115, SNORD109B, and UBE3A-
ATS are expressed exclusively in neurons, concomitant with the use of upstream exons 
of the SNURF-SNRPN gene (10).  Only one imprinted gene is expressed exclusively 
from the maternally-inherited allele: UBE3A (18).  This gene is expressed from both 
parental alleles in most tissues, but is expressed exclusively from the maternally-
inherited allele in neurons.  The tissue-specific imprinted expression of UBE3A occurs to 
due to the tissue-specific expression of UBE3A-ATS from the paternal allele (17, 10, 
65).  Mutations of UBE3A are sufficient to cause AS (66). 
Recently, several individuals with PWS caused by rare, atypical smaller deletions 
have been reported in the literature (42–44).  Together these individuals have 
delineated a smallest region of deletion overlap that underlies the PWS phenotype.  
This smallest region of deletion overlap includes the SNORD116 cluster along with 
other singleton snoRNAs and the ncRNA, IPW.   Interestingly, lymphoblastoid lines from 
two of these individuals were shown to express either SNORD115 or SNORD109B, 
transcripts that are usually restricted to neurons (42, 43).  We sought to determine 
whether non-neural cells from one of these individuals expressed the neuron-specific 
UBE3A-ATS and showed imprinted UBE3A expression.  Here we report the derivation 
and characterization of induced pluripotent stem cells from an individual with a small 
atypical deletion spanning the SNORD116 cluster and IPW ncRNAs.  We demonstrate 
that iPSCs from this individual express UBE3A-ATS and show imprinted UBE3A 
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expression, phenomena that are usually restricted to neurons.  We show that this 
occurs without the expression of the neuron-specific upstream exons of SNURF-
SNRPN, and results in a shortened SNURF-SNRPN/UBE3A-ATS ncRNA that is 
resistant to silencing by the topoisomerase inhibitor, Topotecan.  These data suggest 
that the expression of UBE3A-ATS is sufficient for imprinted UBE3A expression and 
that a boundary element lying within the smallest region of deletion overlap for the PWS 
phenotype prevents the expression of UBE3A-ATS in non-neural tissues. 
 
Materials and Methods 
Cell Lines and Culture Conditions 
AS del 1-0, PWS del 1-1, PWS del 1-7, and NML 1-0 iPSC lines used in this study were 
cultured as described (10).  Moreover, PWS small deletion (PWS SD) iPSC lines were 
derived from patient fibroblasts (43) using the human polycistronic STEMCCA lentiviral 
vector encoding OCT4, KLF4, SOX2, CMYC, and cultured following previously 
published protocols (67).  The iPSC lines were cultured in hESC medium, i.e. 
Dulbecco’s modified Eagle’s medium/F-12 containing 20% KnockOut serum replacer, 
0.1 mM nonessential amino acids, 1 mM L-glutamine (all from Life Technologies, Grand 
Island, NY), 0.1 mM β-mercaptoethanol (Sigma-Aldrich, St. Louis, MO), supplemented 
with 4 ng/ml bFGF (Millipore, Billerica, MA). 
 
Immunocytochemistry:  
Immunocytochemistry was performed as previously described (68), using rabbit anti-
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NANOG (Stemgent, Cambridge, MA), mouse anti-SSEA-4 (Developmental Studies 
Hybridoma Bank, Iowa City, IA), mouse anti-TRA1-60 or mouse anti-TRA1-81 (Santa 
Cruz Biotechnology, Santa Cruz, CA), or mouse anti-MAP2 (Millipore) antibodies.  Cell 
nuclei were counterstained with DAPI. 
 
qRT-PCR 
RNA was isolated from cells using RNA-Bee (Tel Test, Inc., Friendswood, TX), and 
cDNA was synthesized using High Capacity cDNA Reverse Transcription Kit (Life 
Technologies).  Gene expression was analyzed using TaqMan® Gene Expression 
Assays, and the GAPDH Endogenous Control TaqMan® Assay was used as an 
endogenous control.  Experiments were performed in triplicate. The data was analyzed 
using RQ2.1 software (Applied Biosystems), normalized to either NML 1-0 iPSCs or 
NML 1-0 10-week neurons.  The Sybr qRT-PCR primers used to examine the 
expression of SNRPN upstream U2 and U4 exons, relative to the GAPDH endogenous 
control, are listed in Supplementary Table 2. 
 
Methylation-Sensitive Restriction Endonuclease Quantitative PCR Assay 
These assays were performed as described (10).  The Methyl Profiler enzyme kit and 
SNRPN primer set (Qiagen) were used according to the manufacturer’s instructions to 
assay methylation at the PWS-IC. Percent methylation was reported plus or minus the 
SD of three replicates. No intermediate methylation was observed in any of the 
fibroblast or iPSC lines with this assay. The SNRPN primer set assays seven different 
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CpG sites within the PWS-IC. 
 
RT-PCR for UBE3A-ATS 
To examine if the UBE3A-ATS was expressed in the PWS SD iPSC lines, conventional 
PCR primers were used.  RT-19 primers described in Runte et al. (63) were used to 
analyze the expression of the UBE3A-ATS, and GAPDH was used as a loading control.  
NML 1-0 10-week neurons were used as a positive control, since the UBE3A-ATS is 
exclusively expressed in neurons.  
 
Allele-specific RT-PCR 
RNA was extracted from iPSCs using RNA-Bee (Tel Test, Inc.), followed by DNase 
treatment using TURBO DNA-free Kit (Life Technologies AM1907).  1 μg of DNase-
treated RNA was reverse transcribed using Superscript III (Life Technologies) at 53 °C 
with strand-specific primers with tag sequences 
(GGAAACAGCTATGACCATAACAATTTTCCCATTCAGAT for sense, and 
CAGTCGGGCGTCATCATTTTCGTTATTGTTCCTTAGAA for anti-sense; tag 
sequences are shown in bold).  PCR was performed with annealing temperature at 
60°C for 27 cycles using Advantage 2 Polymerase Mix (Clonetech, Mountain View, CA) 
with primer sequences as the following: CATGAGCTTAGACTTCACCTTTCA and 
GGGACCTCATGATGGCAATA.  PCR products were run on precast Novex TBE 6% 
polyacrylamide gel (Life Technologies) and post-stained with SYBR Gold (Life 
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Technologies).  Images were taken using LAS-3000 and the bands were quantified 
using Multigauge V3.0 software (Fujifilm, Tokyo, Japan). 
 
RNA FISH 
iPSCs were grown on MEF-covered 12mm coverslips for 4-6 days.  Prior to 4% 
paraformaldehyde/PBS fixation for 10 minutes, coverslips were treated with CSK buffer 
for 30 seconds, 1% Triton-X100/CSK buffer for 10 minutes, and CSK buffer for 30 
seconds.  Coverslips were then dehydrated with 70%, 85%, 95%, and 100% EtOH for 2 
minutes each and air-dried before hybridizing with probes.  SNORD115 probes were 
made by labeling BAC RP11-37A4 using ENZO Nick Translation DNA Labeling System 
(Enzo, Farmingdale, NY) with Alexa Fluor 594 dUTPs (Life Technologies) according to 
the manufacturer’s instructions.  UBE3A sense riboprobes were made from C7-3 cDNA 
(69) cloned in pBluescript SK+ and in vitro transcribed using the MAXIscript T7/T3 Kit 
(Life Technologies) with Alexa Fluor 488 UTPs (Life Technologies) according to the 
manufacturer’s instructions.  1 μg of the transcribed riboprobes were hydrolyzed in 
carbonate buffer (60 mM Na2CO3 and 40 mM NaHCO3) at 60 °C for 30 minutes and 
neutralized in 1/20 volume of 10% acetic acid prior to purifying labeled riboprobes by 
Micro Bio-Spin P-30 Tris column (Bio-Rad, Hercules, CA).  100 ng of labeled 
SNORD115 was added to the UBE3A purified riboprobes along with 5 μg of human Cot-
1 DNA, 5 μg of salmon sperm DNA, and 2.5 volumes of 100% EtOH.  Probes were 
precipitated at -20 °C for 30 minutes and centrifuged at 12,000 rpm for 30 minutes.  
Probe pellets were air-dried in the dark for 15 minutes and reconstituted in 100% 
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formamide before heat denaturing at 85 °C for 10 minutes.  2 X hybridization buffer (4 X 
SSC, 20% dextran sulfate, 2 mg/mL BSA) was added to the probes and applied equally 
to coverslips for overnight hybridization at 37 °C in a dark humid chamber containing 2 
X SSC/50% formamide.  Coverslips were washed 3 times with 2 X SSC/50% 
formamide, 3 times with 2 X SSC, and 3 times with 1 X SSC for 7 minutes each at 39 °C 
prior to mounting with DAPI (Vectashield, Burlingame, CA).  Images were taken using 
Zeiss 780 confocal microscrope. 
 
Neural differentiation 
10 wk neurons were differentiated from iPSCs using the monolayer protocol as 
described (70).  Briefly, one-day post-split iPSCs were growing in N2B27 medium 
supplemented with 500 ng/mL Noggin (R&D Systems, Minneapolis, MN) for 10 days.  
These colonies were then spilt onto poly-L-lysine and laminin-coated plates using 
StemPro EZ Passage tool (Life Technologies) and kept in N2B27 medium for 7 days.  
Once rosettes were forming in these colonies, the cells were trypsinized and replated 
onto poly-L-lysine and laminin-coated plates at higher density in N2B27 medium 
supplemented with ROCK inhibitor overnight.  The cells were kept in N2B27 medium for 
another 6 days and split onto poly-L-lysine and laminin-coated plates with 1:4 to 1:6 
ratio in neural differentiation media for 2 wks.  The cells were then split with 1:6 ratio for 
another 5 wks in neural differentiation media before topoisomerase inhibitor treatment. 
 
Topoisomerase inhibitor treatment 
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Topoisomerase inhibitor, topotecan (Molcan Corporation, Toronto, Ontario, Canada), 
was dissolved in DMSO (Sigma-Aldrich) to make a 100 mM stock.  A series of dilutions 
was made to achieve the final concentrations of 100 μM, 10 μM, 1 μM, 100 nM, and 10 
nM containing 0.1% DMSO for dose response curve experiments.  The cells were 
treated with various concentrations of topoisomerase inhibitor for continuous 6 days 
prior to collecting RNA for experiments. 
 
Results 
Derivation of iPSCs from PWS small deletion patient 
We obtained PWS patient fibroblasts with a 187 kb microdeletion of paternal 
15q11-q13 (43), and reprogrammed them into iPSCs using the human polycistronic 
STEMCCA lentiviral vector encoding OCT4, KLF4, SOX2, CMYC (67).  The boundaries 
of this deletion are diagrammed in Figure 1.  Reprogrammed colonies were initially 
identified morphologically and were subsequently validated using immunocytochemistry 
to verify the expression of the pluripotency markers NANOG, SSEA-4, TRA1-60, and 
TRA1-81 by immunocytochemistry (Figure 2A).  PWS SD iPSCs had normal karyotypes 
of 46 XY (Supplementary Figure 1), because the microdeletion cannot be detected by 
G-banded karyotyping.  We confirmed the deletion by quantitative RT-PCR for gene 
expression analysis in PWS SD iPSCs for genes within the microdeletion, as described 
in de Smith et al (43).  Expression of SNORD116 and IPW was undetectable in the 
PWS SD iPSCs, compared to the normal iPSC line NML 1-0, while genes located 
outside of the deleted region (NDN, ATP10A, and GABRB3) were expressed in PWS 
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SD iPSCs (Figure 2B).  IPSC lines derived from a PWS patient harboring a large 
deletion of paternal 15q11-q13 (PWS del 1-7), as well as from an AS patient with a large 
deletion of maternal 15q11-q13 (AS del 1-0), were used as controls (10).  The 
boundaries of these deletions are also shown in Figure 1.  PWS del 1-7 iPSCs did not 
express the paternally expressed genes NDN, SNORD116 and IPW as expected, but 
expressed ATP10A and GABRB3, while AS del 1-0 iPSCs expressed SNORD116 and 
IPW, as well as NDN, ATP10A and GABRB3 (Figure 2B).  To determine if the 
differential methylation that marks the PWS-IC was maintained during reprogramming, 
the methylation imprint of the PWS-IC was assessed in PWS SD fibroblasts and iPSCs 
by methylation-sensitive restriction endonuclease quantitative PCR.  Only an 
unmethylated paternal allele was observed in AS del 1-0 iPSCs, while only a methylated 
maternal allele was observed in PWS del 1-7 iPSCs, as previously described (10).  Both 
a methylated maternal allele and an unmethylated paternal allele were present in all of 
the PWS SD fibroblasts and iPSC lines (Figure 2C), with percent methylation ranging 
from 42 to 50% in most iPSC lines.  The PWS SD 2-1 iPSC line appeared to have 
aberrant methylation of the PWS-IC, and was excluded from further study.  The 
remaining PWS SD iPSC lines had methylation levels approximately equal to the PWS 
SD fibroblast line.  To confirm that the PWS SD iPSC lines were capable of multi-
lineage differentiation, the cells were differentiated into embryoid bodies (EBs).  After 16 
days of spontaneous differentiation, the EBs were collected and analyzed by qRT-PCR 
for lineage markers for all three germ layers, using a custom-designed TaqMan® 
scorecard that incorporated lineage markers described in Bock et al (71).  AS del 1-0, 
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PWS del 1-7, and NML 1-0 iPSCs were used as positive controls in these assays.  Early 
lineage markers representing each of the three embryonic germ layers were expressed 
in the EBs derived from each of the PWS SD iPSCs (Supplementary Figure 2), 
demonstrating that they are capable of multi-lineage differentiation. 
 
Paternal UBE3A is imprinted in non-neuronal cells 
Two recent studies reported the expression of either SNORD115 or 
SNORD109B, transcripts that are normally restricted to neurons, in PWS SD patient 
lymphocytes (42, 43).  To determine whether the neuron-specific gene was also 
expressed in PWS SD iPSCs, we performed qRT-PCR for SNORD115.  In agreement 
with the expression data from lymphocytes, robust expression of SNORD115 was 
observed in PWS SD iPSCs (Figure 3A).  We then performed conventional RT-PCR for 
UBE3A-ATS to determine whether this transcript extended into the UBE3A gene.  
Strong expression of UBE3A-ATS was observed using primers anchored in exons 
exclusive to UBE3A-ATS (Figure 3B).  Since UBE3A-ATS was expressed, we 
hypothesized that UBE3A expression would be imprinted; the expression of paternal 
UBE3A-ATS in neurons represses paternal UBE3A expression (17, 10, 65).  We first 
tested this hypothesis using qRT-PCR to determine UBE3A mRNA levels in PWS SD 
iPSCs.   Normal iPSCs have twice as much UBE3A mRNA, as compared to AS and 
PWS iPSCs with large deletions of chromosome 15q11-q13 (Figure 3C).  This most 
likely occurs because UBE3A expression is bi-allelic in iPSCs.  Normal iPSCs have two 
copies of UBE3A, while AS and PWS iPSCs harbor a large deletion of chromosome 
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15q11-q13 with only a single copy of UBE3A.   Although PWS SD iPSCs have two intact 
copies of UBE3A, its relative expression is half of the normal iPSCs and similar to both 
AS and PWS iPSCs, where there is only one copy of UBE3A (Figure 3C).  This 
suggests that UBE3A may be imprinted in the PWS SD iPSCs.  
In order to determine whether one copy of UBE3A is repressed, we performed 
allele-specific RT-PCR analysis of UBE3A expression.  We first screened most of the 
UBE3A cDNA to identify allele-specific polymorphisms. Upon finding no polymorphisms 
in the cDNA, we then scanned the introns in the hopes that a polymorphism in the pre-
mRNA could be used to determine allele-specific expression.  We identified a 
polymorphism in intron 9 of UBE3A where one allele has 5 copies of a 26 nucleotide 
repeat and the other allele has 4 copies of this repeat in PWS SD iPSCs. The normal 
iPSC line is also polymorphic at this site, with different numbers of repeats.  We 
performed semi-quantitative strand-specific RT-PCR using primers flanking this 
polymorphism to determine the allele-specific expression of UBE3A sense pre-mRNA 
transcripts.  As expected, the UBE3A sense is transcribed equally from both alleles in 
the normal iPSC line.  In PWS SD iPSCs, however, most of the UBE3A sense transcript 
comes from only a single allele, presumably due to the aberrant expression of UBE3A-
ATS from the paternal allele in these iPSCs (Figure 3D). 
To further confirm that the paternally inherited allele of UBE3A is silenced and 
the maternally inherited allele is expressed in PWS SD iPSCs, we performed RNA FISH 
using a riboprobe that specifically detects UBE3A sense transcripts and a BAC probe 
that detects SNORD115 transcripts.  In normal iPSCs, UBE3A is actively transcribed 
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from both alleles, and SNORD115 transcripts are not detected, as expected (Figure 3E, 
left panel).  In PWS SD iPSCs, most of the cells have a single expressed copy of 
UBE3A that does not co-localize with the single expressed copy of SNORD115, 
demonstrating that paternal UBE3A is repressed, presumably by the expression of 
UBE3A-ATS (Figure 3E, middle and right panels).  Notably, a small portion of cells (17% 
+ 2%) still express UBE3A from both parental alleles even though they produce 
SNORD115, indicated by the asterisk (Figure 3E, right panel).  
 
SNRPN upstream exon usage is not affected in PWS SD iPSCs and neurons 
In brain, expression of UBE3A-ATS and imprinted UBE3A expression occurs 
concomitantly with the use of several upstream exons of SNURF-SNRPN, diagrammed 
in Figure 4A.  Use of these upstream exons is thought to shift expression from the 
protein coding exons of SNURF-SNRPN to the non-coding downstream exons (72).  In 
humans, at least one upstream SNURF-SNRPN exon is used in many non-neural 
tissues.  Coincidently, downstream ncRNAs between and SNURF-SNRPN and IPW 
(inclusive of IPW) are expressed in many tissues, including iPSCs. To determine 
whether the aberrant expression of UBE3A-ATS correlated with the use of the neuron-
specific upstream exons of SNURF-SNRPN, we differentiated the PWS SD iPSCs into 
neurons to compare upstream exon usage between neural and non-neural tissue. 
In order to choose PWS SD iPSC lines that are capable of efficient differentiation 
into neurons, we examined the expression levels of genes critical for specification into 
the neural lineage in d16 EBs (Supplementary Figure 3A), using the scorecard 
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described above.  In addition to the lineage markers used to verify multi-lineage 
differentiation potential, this card also had probe-primer sets for an abbreviated list of 
widely used neural lineage marker genes (Supplementary Table 1) (71).  Probe-primer 
sets to the pluripotency genes NANOG and ZFP42/REX1 were also included in the 
scorecard to determine whether pluripotency genes were appropriately turned off during 
differentiation (Supplementary Figure 3B).  We used AS del 1-0 as a calibrator sample 
for these assays, since this AS iPSC line differentiates robustly into neurons using 
conventional neural differentiation assays (10).  The PWS del 1-1 iPSC line was used 
as a negative control for these assays, since it does not robustly differentiate into 
neurons.  Differentiation propensity of the PWS SD iPSC lines into neurons was 
determined based two criteria: 1.) robust expression of neural lineage markers, and 2.) 
silencing of the pluripotency genes. PWS SD 2-8 and PWS SD 2-9 iPSC lines were 
found to have the highest propensities to differentiate into neurons, due to the robust 
expression of neural lineage markers and silencing of the pluripotency genes.  Despite 
the robust expression of the neural lineage markers in the PWS SD 2-4 iPSC line, this 
line may have limited differentiation potential in conventional neural differentiation 
assays due to the inappropriate expression of the pluripotency genes in d16 EBs.  PWS 
SD 2-8 and PWS 2-9 iPSC lines were chosen for further analysis.  
Both PWS SD 2-8 and PWS SD 2-9 iPSC lines were differentiated into neurons, 
as previously described (10).  Following 10 weeks of differentiation, MAP2-positive 
neurons were identified by immunocytochemistry.  A representative image is shown for 
10-week PWS SD 2-8 iPSC-derived neurons (Figure 4B).  The expression of the 
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neuron-specific upstream U1A, U2, and U4 exons was compared between PWS SD 
iPSCs and PWS SD iPSC-derived neurons by quantitative RT-PCR (Figure 4C).  The 
U1A and U2 exons were almost exclusively expressed in the neuron samples and were 
nearly undetectable in all six iPSC lines.  Exon U4, which showed robust expression in 
NML 1-0, PWS SD 2-8, and PWS SD 2-9 iPSC-derived neurons, was expressed at low 
levels in NML 1-0 and AS del 1-0 iPSCs, was barely detectable in PWS SD iPSCs, and 
was undetectable in PWS del 1-7 iPSCs.  Thus, imprinted expression of UBE3A in PWS 
SD iPSCs was not caused by the aberrant expression of the neuron-specific upstream 
SNRPN exons.  Moreover, these results suggest that expression of UBE3A-ATS is 
sufficient for imprinted expression of UBE3A and that additional neuron-specific events 
were not required for this imprinting in non-neural tissues. 
 
The shortened UBE3A-ATS in PWS SD neurons is less amenable to silencing by 
Topotecan 
Topoisomerase inhibitors have been shown to repress Ube3a-ats in mouse (26).  
This effect is length-dependent and is shared between mouse and human across the 
genome, with longer genes showing greater repression by topoisomerase inhibitors 
(73).  Since the UBE3A-ATS transcript is reduced by 187 kb in PWS SD iPSCs, we 
sought to determine whether a topoisomerase inhibitor was less effective on the 
shortened UBE3A-ATS transcript.  We treated 10-week old AS and PWS SD iPSC-
derived neurons with increasing doses of Topotecan, a campothecin-type 
topoisomerase inhibitor that was previously shown to be effective at reducing mouse 
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Ube3a-ats.  We then performed qRT-PCR using a probe-primer set that recognizes the 
SNURF-SNRPN ncRNA in the region of SNORD115.  This SNORD115 host transcript 
can be used as a proxy for UBE3A-ATS, and thus avoids possible confusion with the 
sense UBE3A transcript.  Topotecan was highly effective in reducing the SNURF-
SNRPN ncRNA (which includes UBE3A-ATS) in AS iPSC-derived neurons, showing 
90% reduction of the transcript at a 10 μM dose (Figure 5).  However, topotecan was 
less effective in repressing the shortened SNURF-SNRPN ncRNA in PWS SD neurons, 
only showing a maximum 46% reduction compared to the 90% reduction seen in AS 
neurons (Figure 5).  
 
Discussion 
Here we show that iPSCs derived from patients with PWS due to a small deletion 
on paternal chromosome 15q11-q13 express UBE3A-ATS and have imprinted 
expression of UBE3A.  UBE3A-ATS expression is typically restricted to neurons, and 
consequently so is UBE3A imprinting.   Work over the past decade has steadily focused 
on UBE3A-ATS as the mediator of UBE3A imprinted expression (17, 10, 65, 74).  Thus, 
understanding the neuron-specific regulation of UBE3A-ATS is critical for understanding 
the regulation of UBE3A imprinted expression.   
UBE3A-ATS is within the neuron-specific portion of the SNURF-SNRPN ncRNA, 
which also includes SNORD115 and SNORD109B (63).  In non-neuronal tissues and 
cell types, transcription of the SNURF-SNRPN locus usually stops at IPW, and thus 
SNORD115, SNORD109B, and UBE3A-ATS are not expressed (10).  In contrast to 
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normal iPSCs where the neuron-specific portion of SNURF-SNRPN is not expressed, 
PWS SD iPSCs showed robust expression of SNORD115 and UBE3A-ATS (Figures 3A 
and 3B).  In normal iPSCs, the polyadenylation sites that lie at the 3’ end of IPW are 
likely transcriptional stops for the SNURF-SNRPN transcript.  These sites, as well as 
additional as-of-yet unidentified regulatory elements, have been removed in the PWS 
SD patient derived iPSCs, placing the SNURF-SNRPN promoter and exon 1 in direct 
association with the SNORD115 portion of the transcript.  The identification of the 
regulatory elements that stop SNURF-SNRPN transcription will be an important clue in 
understanding the neuron-specific regulation of UBE3A-ATS and imprinted UBE3A 
expression.  Alternatively, the SNURF-SNRPN transcript is terminated at IPW because 
that is the maximum length that can be transcribed during the iPSC cell cycle. 
The aberrant expression of UBE3A-ATS transcript in PWS SD iPSCs leads to 
imprinted UBE3A expression (Figure 3).  We demonstrated this in three ways.  First, we 
determined UBE3A expression levels.  UBE3A mRNA levels in PWS SD iPSCs are 
consistent with having only a single expressed allele of the gene, like PWS and AS 
iPSCs harboring large deletions of paternal and maternal chromosome 15q11-q13, 
respectively.  Normal iPSCs have UBE3A mRNA levels consistent with having two 
expressed copies of the gene (Figure 3C).  Secondly, we determined whether UBE3A is 
expressed from one or two alleles in PWS SD iPSCs using strand-specific RT-PCR.  
UBE3A is primarily expressed from a single allele in these cells, and UBE3A-ATS is 
expressed exclusively from the opposite allele (Figure 3D).  Finally, we used RNA FISH 
to confirm that UBE3A was coming from a single allele that did not produce the 
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SNORD115 transcript (Figure 3E).  These data suggest that UBE3A-ATS expression is 
sufficient for the imprinted expression of UBE3A, and that additional neuron-specific 
factors are not necessary for the repression of paternal UBE3A.  
Interestingly, imprinting of UBE3A is not complete in every cell, as evidenced by 
both the RT-PCR and RNA FISH data.  In fact, the RNA FISH data demonstrated that 
approximately 20% of the cells showed juxtaposed UBE3A and SNORD115 expression 
in the same cell (Figure 3E).  While we do not know the exact reason for this, we 
speculate that in the dividing PWS SD iPSCs, replication may cause the premature 
termination of the SNURF-SNRPN/SNORD115 transcript prior to overlapping UBE3A, 
thus allowing UBE3A transcription in the sense direction.  Indeed, paternal Ube3a has 
been shown to retain active histone modifications, even in brain (75).  The PWS SD 
iPSCs described here show that imprinted UBE3A expression can be maintained by the 
UBE3A-ATS, even in the presence of a transcriptionally-competent paternal UBE3A 
promoter.   It is therefore not necessary that paternal UBE3A undergoes repressive 
chromatin changes, even in neurons where it is normally imprinted.   
There was a slight discrepancy between the FISH and RT-PCR data.  The FISH 
data showed that 17%+/-2% of cells showed detectable expression from the paternal 
allele of UBE3A (Figure 3E, lower panel), while the RT-PCR data showed that 27% of 
the total UBE3A RNA came from the paternal allele (Figure 3D).  There are at least 
three possible explanations for this:  1.) the FISH assay failed to detect UBE3A in some 
cells where it was expressed from the paternal allele at a level lower than the detection 
limit;  2.) the active paternal allele is expressing more UBE3A than the maternal allele in 
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some or all of the cells, so that ~17% of the cells are producing ~27% of the RNA; or 3.) 
the semi-quantitative RT-PCR experiment may suffer from amplification bias or 
measurement bias (i.e. the genomic DNA in PWS SD 2-8 was measured as 54% 
paternal and 46% maternal). 
Topoisomerase inhibitors were shown to reactivate the paternal allele of Ube3a 
in mouse neurons by repressing Snurf-Snrpn/Ube3a-ats (26).  This occurs because 
topoisomerases are required for efficient transcription of long genes in both human and 
mouse neurons (73).  The 187 kb deletion of the SNORD116 cluster enabled us to 
examine the effect of a topoisomerase inhibitor, topotecan, on a shortened SNURF-
SNRPN/UBE3A-ATS transcript.  We found that topotecan was not as effective on the 
shortened UBE3A-ATS transcript as it was on the full-length transcript, further 
supporting the observation that topoisomerases are important for the transcription of 
UBE3A-ATS and other long genes (Figure 5).   
Altogether, these data demonstrate that the SNURF-SNRPN transcript is 
regulated by a boundary element in non-neurons, and that in its absence, the 
expression of UBE3A-ATS is sufficient to cause UBE3A imprinted expression in the 
absence of additional neural factors.   We do not know what comprises this boundary 
element, but we speculate that either the polyadenylation sites in the IPW gene act as 
transcriptional terminators, that CTCF protein binding sites downstream of IPW separate 
active versus inactive chromatin territories, or a combination of those two possibilities 
work to perform the boundary function.  These findings provide important clues as to the 
regulation of the SNURF-SNRPN ncRNA in humans.  Furthermore, they demonstrate 
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that iPSCs derived from rare individuals with atypical deletions can teach us important 
lessons about the mechanisms of gene regulation. 
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Figure 1.  Map of chromosome 15q11-q13 region.  Map of chromosome 15q11-q13 
between common break points 2 and 3 (BP2 and BP3).  Blue dotted lines represent the 
regions deleted on the paternal allele, and red dotted line represents the regions deleted 
on the maternal allele for the indicated cell lines.  Blue and red boxes denote genes 
expressed exclusively from paternal and maternal alleles, respectively.  Grey boxes 
denote genes expressed biallelically.  Differential methylated regions (DMRs) are shown 
using circles where open and closed circles represent unmethylated and methylated 
alleles, respectively.  Arrows indicate the direction of transcription.  A solid blue line 
represents paternal SNURF/SNRPN transcripts expressed in most cell types, whereas 
a dashed blue line indicates neuron-specific transcripts, including UBE3A-ATS. 
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Figure 2.  Characterization of PWS SD iPSC lines.   A.) Immunocytochemistry for the 
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pluripotency markers NANOG, SSEA-4, TRA1-80, and TRA1-81.  Cell nuclei were 
counterstained with DAPI.  Scale bar = 100 μm.  B.) Expression of genes within 15q11-
q13 region iPSCs to confirm deletion in PWS SD iPSCs.  GAPDH was used as en 
endogenous control, and data was normalized to NML 1-0 iPSCs.  C.) Methylation 
analysis of PWS-IC within SNPRN, using a methylation-sensitive restriction 
endonuclease quantitative PCR assay, confirming the maintenance of genomic 
imprinting at the PWS-IC following reprogramming in PWS SD iPSCs.  PWS del 1-7 and 
AS del 1-0 iPSCs were used as controls.  Percent methylation was reported plus or 
minus the SD of three replicates.   
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Figure 3.  Imprinting of paternal UBE3A in non-neuronal cells. A.) Gene expression 
analysis of SNORD115 snoRNAs in iPSCs by qRT-PCR.  GAPDH was used as an 
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endogenous control, and data was normalized to NML 1-0 10-week neurons. B.) 
Analysis of UBE3A-ATS expression in PWS SD iPSCs.  RT-19 primers were used to 
analyze the expression of the UBE3A-ATS (63), and GAPDH was used as a control.  
NML 1-0 10-week neurons were used as a positive control, since the UBE3A-ATS is 
exclusively expressed in neurons.  C.) Expression analysis of UBE3A in iPSCs.  
GAPDH was used as an endogenous control, and data was normalized to NML 1-0 
iPSCs.  PWS del 1-7 and AS del 1-0 iPSCs were used as controls.  D.) Allele-specific 
RT-PCR showed equal expression of UBE3A in NML 1-0 iPSCs.  In PWS SD iPSCs, the 
paternal UBE3A is repressed while UBE3A-ATS is expressed (S=sense, 
ATS=antisense, and GM=genomic DNA).  E.) RNA FISH using a riboprobe that 
specifically detects UBE3A sense transcripts (green) and a BAC probe that detects 
SNORD115 transcripts (red).  UBE3A is actively transcribed from both alleles, and 
SNORD115 transcripts are not detected in NML 1-0 iPSCs.  Scale bars = 5 μm.  In 
PWS SD iPSCs, 83% of SNORD115-positive nuclei showed monoallelic expression of 
UBE3A and 17% of that showed biallelic expression of UBE3A, as indicated by the 
asterisk. 
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Figure 4.  SNRPN upstream exon usage in PWS SD iPSCs neurons.  A.) Map 
showing the organization of upstream SNURF-SNRPN exons (76).  Upstream exons 
U1B, U1B’, U1A, and U2 are largely neuron-specific, as indicated by the bracket.  Exon 
U4 is expressed at low levels in a variety of tissues, including iPSCs.  It is unclear 
whether U3 and U5 are brain-specific.  The location of the PWS-IC is indicated by a 
half-filled circle.  B.) Immunocytochemistry for the neural marker MAP2 in PWS SD 2-8 
10-week neurons.  Cell nuclei were counterstained with DAPI.  Scale bar = 100 μm.  C.) 
Expression analysis of upstream SNRPN exons.  GAPDH was used as an endogenous 
control, and data was normalized to NML 1-0 10-week neurons, since these exons are 
predominately expressed in neurons. 
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Figure 5.  Topotecan is less effective in repressing the UBE3A-ATS in PWS SD 
neurons.  Relative expression of SNORD115 by qRT-PCR in 10 wk neurons derived 
from PWS SD and AS iPSC lines treated with various concentrations of Topotecan.  
GAPDH was used as an endogenous control.  ** p-value < 0.05 
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Supplementary methods 
qRT-PCR: After 16 days of spontaneous differentiation, embryoid bodies (EBs) 
representative of each iPSC line were collected, RNA was extracted using RNA-Bee 
(Tel Test, Inc.), and cDNA was synthesized using High Capacity cDNA Reverse 
Transcription Kit (Life Technologies).  A custom designed TaqMan® Gene Signature 
Array Card (Life Technologies) was developed to include lineage marker genes 
representative of all three germ layers adapted from Bock et al (71) (Supplementary 
Table 1). For lineage marker expression, CT values were normalized to those of 18S 
rRNA using RQ manager software (Applied Biosystems), generating a ΔCT value for 
each gene on the array, which indicates the relative expression levels.  Expression 
levels as a percentage of GAPDH were reported for each lineage marker gene, as 
described (10). 
 To determine the neural differentiation propensities of each iPSC line, an 
abbreviated list of neural lineage markers described in Bock et al (71), as well as 
additional widely used neural lineage marker genes, were included in the custom 
designed TaqMan® Gene Signature Array Card (Life Technologies; Supplementary 
Table 1).  The pluripotency genes NANOG and ZFP42/REX1 were also included in the 
array card.  D16 EBs were collected, and gene expression was analyzed as described 
above.  Data was normalized to AS del 1-0 d16 EBs and displayed as Log2 ratio.   
 
Karyotype Analysis: Karyotype analysis was performed on PWS SD 2-8 and PWS SD 2-
9 iPSC lines by the iPSC & Chromosome Core at the University of Connecticut Health 
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Center on G-banded metaphase cells, using standard protocols for high resolution G-
banding.  20 metaphase cells were counted for each iPSC line.   
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Supplementary Table 1.  Taqman Assays printed on custom card 
 
Gene Taqman Assay ID Gene Taqman Assay ID 
ITGAX Hs01015070_m1 LMX1A Hs00602600_m1 
HHEX Hs00242160_m1 TWIST1 Hs00361186_m1 
LEF1 Hs01547250_m1 PAX6 Hs01088112_m1 
TNFRSF1A Hs01042313_m1 NOTCH1 Hs01062014_m1 
ADIPOQ Hs00605917_m1 NES Hs00707120_s1 
T Hs00610080_m1 ITGA6 Hs01041011_m1 
KIT Hs00174029_m1 NEUROG1 Hs01029249_s1 
SRF Hs00182371_m1 FGF2 Hs00266645_m1 
INHBA Hs01081598_m1 EPHB4 Hs00174752_m1 
ANPEP Hs00952642_m1 OLIG2 Hs00377820_m1 
MME Hs00153510_m1 MAP2 Hs00258900_m1 
ITGAL Hs00158218_m1 ICAM1 Hs00164932_m1 
FOXA2 Hs00232764_m1 FAS Hs00531110_m1 
CDX2 Hs01078080_m1 DLX5 Hs00193291_m1 
HNF1A Hs00167041_m1 FGFR3 Hs00179829_m1 
GATA6 Hs00232018_m1 MSI1 Hs00159291_m1 
GCG Hs01031536_m1 EOMES Hs00172872_m1 
NEUROG3 Hs01875204_s1 CDH2 Hs00983056_m1 
CD44 Hs01075861_m1 MAPT Hs00902194_m1 
GATA4 Hs00171403_m1 ISL1 Hs00158126_m1 
PDX1 Hs00426216_m1 SYP Hs00300531_m1 
SLC2A2 Hs01096904_m1 ITGAM Hs00355885_m1 
NKX2-5 Hs00231763_m1 MNX1 Hs00907365_m1 
SST Hs00174949_m1 TH Hs00165941_m1 
NR2E1 Hs01128417_m1 SOX1 Hs01057642_s1 
SNAI2 Hs00950344_m1 DLL1 Hs00194509_m1 
APOE Hs00171168_m1 TBR1 Hs00232429_m1 
SOX9 Hs00165814_m1 PAX7 Hs00242962_m1 
BMP2 Hs00154192_m1 PAX2 Hs01057416_m1 
ABCG2 Hs01053790_m1 CRABP2 Hs00275636_m1 
FUT4 Hs01106466_s1 NEUROG2 Hs00702774_s1 
MCAM Hs00174838_m1 FOXG1 Hs01850784_s1 
FOXD3 Hs00255287_s1 EMX1 Hs00417957_m1 
NEFL Hs00196245_m1 GBX2 Hs00230965_m1 
SOX4 Hs00268388_s1 EN1 Hs00154977_m1 
THY1 Hs00174816_m1 HOXB4 Hs00256884_m1 
TCF4 Hs00971331_m1 OTX2 Hs00222238_m1 
PAX3 Hs00240950_m1 NEUROD1 Hs00159598_m1 
NCAM1 Hs00941821_m1 SOX2 Hs01053049_s1 
CD34 Hs00990732_m1 KLF4 Hs00358836_m1 
SOX10 Hs00366918_m1 ZFP42 Hs01938187_s1 
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ITGB1 Hs00559595_m1 NANOG Hs02387400_g1 
ITGA4 Hs00168433_m1 SHH Hs00179843_m1 
TCF3 Hs01012685_m1 CAMK2A Hs00392405_m1 
NOG Hs00271352_s1 CEACAM1 Hs00236077_m1 
NGFR Hs00609976_m1 ACTB Hs99999903_m1 
CEACAM5 Hs00944025_m1 GAPDH Hs02758991_g1 
SDC1 Hs00896423_m1 18S Hs03003631_g1 
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Supplementary Figure 1.  Cytogenetic analysis of PWS SD iPSCs.  G-banded 
karyotype analysis of PWS SD 2-8 iPSCs passage (p) 22, and PWS SD 2-9 iPSCs p22. 
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Supplementary Figure 2.  Multi-lineage differentiation capacity of PWS SD iPSCs.  
Lineage marker analysis for expression of genes representing all three germ layers in 
day 16 spontaneously differentiated EBs.  CT values were normalized to 18S rRNA, 
generating a ΔCT value for each gene on the array to indicate relative expression 
levels.  Expression levels are displayed as a percentage of GAPDH for each lineage 
marker gene.  AS del 1-0, PWS del 1-7, and NML 1-0 iPSCs were used as positive 
controls. 
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Supplementary Figure 3.  Differentiation propensity of PWS SD iPSCs into 
neurons. The iPSC lines were spontaneously differentiated into d16 EBs. 18S rRNA 
was used as an endogenous control, and data was normalized to AS del 1-0 d16 EBs, 
since this AS iPSC line differentiates robustly into neurons using conventional neural 
differentiation assays.   Data was displayed as Log 2.  PWS del 1-1 iPSC line was used 
as a negative control for these assays, since it does not robustly differentiate into 
neurons.  Differentiation criteria: 1.) robust expression of neural lineage markers, and 2.) 
silencing of the pluripotency genes. 
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Introduction 
Angelman Syndrome (AS) is a neurodevelopmental disorder characterized by 
developmental delay, speech impairment, ataxia, and severe intellectual disability (77–
79).  It is caused by mutation (66, 80) or deletion (23, 24) of the maternally inherited 
allele of UBE3A.  The loss of maternally inherited UBE3A cannot be compensated from 
the paternally inherited copy because it is imprinted in a tissue-specific manner in the 
brain (18, 25).  The imprinting is controlled by a reciprocal neuronal-specific UBE3A-
ATS (UBE3A-ATS) transcript (17).  This transcript is part of the >600 kb 
SNURF/SNRPN long non-coding RNA (lncRNA) transcription unit initiated from the 
paternal SNURF/SNRPN promoter (63).  The maternal SNURF/SNRPN promoter, 
however, is completely inactive due to methylation at the promoter (56, 81, 82).  The 
paternal SNURF/SNRPN lncRNA can be further divided into two clusters according to 
their tissue-specific transcription patterns in human (10).  The proximal cluster, which 
includes protein-coding SNURF/SNRPN, non-coding small nucleolar RNA 116 
(SNORD116), and non-coding IPW, is ubiquitously transcribed in all tissues.  The distal 
cluster, which includes non-coding small nucleolar RNA 115 (SNORD115), and non-
coding UBE3A-ATS, is transcribed most abundantly in the brain, and barely detected in 
other tissues (83). 
We previously reported that the distal portion of SNURF/SNRPN lncRNA is 
expressed in induced pluripotent stem cells (iPSCs) derived from an individual with an 
atypical paternal deletion (12).  This paternal deletion spans from SNURF/SNRPN intron 
1 to downstream of PWAR1, an exon originally identified amongst SNRPN transcripts 
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isolated from cultured cells (16).  The deletion includes a region separating the 
transcribed proximal portion of SNURF/SNRPN lncRNA from the non-transcribed distal 
portion.  In addition, at least one other individual with an atypical paternal deletion 
including this region also showed expression of the distal portion of SNURF/SNRPN 
lncRNA in a non-neuronal cell type, such as peripheral blood mononucleocytes (42).  
These unique paternal deletions provided evidence that imprinting of UBE3A can occur 
in non-neuronal tissues.  Therefore, we hypothesized that the expression of distal 
SNURF/SNRPN and UBE3A imprinted expression is controlled by the presence of a 
chromatin boundary within this critical region.  We speculated that polyadenylation 
sequences at IPW and/or a cluster of CTCF binding at PWAR1 in this region 
independently or collectively act as transcriptional terminators in non-neuronal cells 
(12). 
Here, we used CRISPR/Cas9 to remove IPW and PWAR1, revealing that these 
two components collectively serve as a bipartite boundary to regulate the distal portion 
of SNURF/SNRPN lncRNA.  SNORD115 and UBE3A-ATS, two portions of the distal 
SNURF/SNRPN lncRNA, were detected in iPSCs in which the putative boundary is 
removed.  We also provide evidence that these two elements are directional.  Disruption 
of the boundary causes irregular imprinting of UBE3A during neural differentiation 
process.  Deletion of the boundary leads to early imprinting of UBE3A whereas 
inversion of it perturbs UBE3A imprinting in neurons.  In addition, we showed that 
directly attaching the SNURF/SNRPN promoter to the UBE3A-ATS portion of the 
lncRNA causes complete imprinting of UBE3A in iPSCs. 
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Materials and Methods 
Cell Culture 
AS iPSC (AS del 1-0) and PWS iPSC (PWS del 1-7) lines were generated and 
maintained as previously described.  Briefly, iPSCs were cultured in hESC medium with 
the following components.  Dulbecco’s modified Eagle’s medium/F-12, 20% Knock-Out 
serum replacer, 0.1 mM non-essential amino acids, 1 mM L-glutamine, 0.1 mM b-
mercaptoethanol, and 4 ng/mL bFGF.  Colonies were grown on MEF and split every 
week. 
 
ChIP qPCR 
ChIP qPCR was performed using Millipore EZ-Magna ChIP G – Chromatin 
Immunoprecipitation Kit (17-409) following manufacturer’s instructions.  Briefly, 6-10 
million cells were used for fixation.  Sonication took place in 0.5 mL of nuclear lysis 
buffer.  4 uL of ChIPAb+ CTCF (17-10044) antibody was added to a 50 uL of sonicated 
DNA aliquot with 450 uL ChIP dilution buffer for immunoprecipitation overnight.  The 
washed immune-DNA complexes were reverse-crosslinked in 100 uL ChIP Elution 
buffer.  Instead of using provided column for DNA purification, the process was carried 
out using phenol-chloroform.  200 uL of nucleases water and 200 uL of phenol-
chloroform were added to the 100 uL ChIP Elution buffer.  After centrifugation, aqueous 
phase was transferred to a new tube.  200 uL of chloroform was added for extra step of 
purification.  The aqueous phase was transferred to a new tube and the precipitation 
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took place at -20 for 30 minutes after adding 1 mL of 100% ethanol, 4 ug of glycogen, 
and 1/10 of total volume of 5M NaCl.  After centrifugation, the DNA pellet was washed 
with 75% ethanol.  50 uL of nuclease-free water was added to the DNA pellet after 
ethanol evaporated.  The DNA was further diluted in a 1:5 ratio for qPCR.  5 uL of 
diluted DNA was added to a 20 uL reaction using SYBR green PCR master mix from 
Thermo Fisher Scientific (4309155).  qPCR primers are list in table 1. 
 
ChIP-seq 
ChIP material was obtained following the same process in ChIP qPCR.  Library 
preparation and sequencing run were performed at Yale sequencing core.  Obtained 
FASTQ files were mapped and analyzed using Homer with the parameters described 
previously. 
 
CRISPR and single-strand oligonucleotide (ssODN) design 
CRISPR gRNA sequences were designed using CRISPR Genome Engineering 
Resource (http://crispr.mit.edu) (84).  The gRNA sequence was cloned in px459 V2 
vector following the published protocol (85, 86).  ssODN was designed following the 
previously described protocol (87).  The CRISPR sequences used in this paper are 
listed in table 2. 
 
Electroporation and clone-screening for genomic deletion 
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6-10 million AS iPSCs were treated with ROCKi (Calbiochem; Y-27632) 24 hours prior 
to electroporation.  iPSC colonies were singlized with Accutase for 30 minutes.  Cells 
were resuspended in 800 uL of cold PBS and 10 ug of each CRISPR flanking the 
desired deletion was added before electroporation using BioRad Gene Pulser Xcell with 
the following conditions: 250 V, 500 uF, 0.4 cm cuvettes (88).  In the case of loxP 
insertion, 2 single stranded oligonucleotides were also added along with 2 CRIRPR 
plasmids.  Electroporated cells were transferred to a 15 conical tubes and centrifuged at 
1000 rpm for 3 minutes to remove debris (89).  Cells were then resuspended in hESC 
media and seeded on DR4 MEFs supplemented with ROCKi for the first 24 hours after 
electroporation.  In the next 48 hours, 1 ug/ml puromycin was used to select cells 
receiving the CRISPR plasmids.  Medium was changed every 24 hours during this 
period.  After drug selection, regular hESC medium was changed everyday until 
colonies were formed.  Colonies were picked to screen for deletion with primers 
designed as previously described.  Primers were designed as described (90) and are 
listed in Table 3 . 
 
4C-seq 
The following procedure of harvesting nuclei was described previously (91).  
Approximately 2 million of iPSCs and iPSC-derived neurons were fixed in formaldehyde 
(1% final) and quenched in glycine (150 mM final) at room temperature on a shaker for 
10 and 5 minutes, respectively.  Cells were harvested and centrifuged for 5 minutes at 
2000 g at 4 C.  Cell pellets were lyzed in 1 mL of cell lysis buffer containing proteinase 
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inhibitor cocktail 3 (Calbiochem) on ice for 20 minutes prior to douncing with pestle A for 
10 strokes and pestle B for 30 strokes.  The nuclei were collected at 2000 g, 4C for 5 
minutes, washed and resuspend in 500 uL of 1x restriction enzyme buffer (NEB 
Cutsmart).  The following 4C material preparation procedure was adapted from 
previously described protocols (92).  The nuclei in NEB cutsmart buffer was incubated 
at 65 C for 10 minutes on a thermal mixer with 800 rpm after adding 15 uL of 10% SDS.  
150 uL of 10% Triton X-100 was added and incubated at 37 for 10 minutes on a nutator.  
200 units of Nla3 (NEB) and 16.5 uL 10x NEB cutsmart were added for the fist digestion 
at 37 C overnight on a nutator.  Additional 50 units of Nla3 for 2 hours were used to 
ensure complete digestion.  Nla3 were heat inactivated prior to spliting into 3 ligations 
reaction.  Each ligation solutions were prepared on ice with the following components: 
220 uL heat inactivated digested material, 745 uL of 10X T4 Ligase buffer, 745 uL 10% 
Triton X-100, 800 ug BSA, 5.5 mL nuclease-free water, and 2000 unit of NEB T4 DNA 
ligase.  Prepared ligation solutions were incubated at 15 C overnight.  15 uL of 20 mg/ml 
proteinase K (NEB) was added to the ligation solution, and incubated at 65C overnight 
to reverse crosslinking.  Reverse-crosslinked 3C material was purified using phenol-
chloroform followed by chloroform prior to ethanol precipitation overnight.  The 3C 
library was pelleted, air-dried, and resuspended in 10 mM Tris-HCl (pH 8.0).  The 
second digestion was performed at 37 C overnight with components listed in the 
followings: 445 uL of 3C library, 50 uL of 10X Dpn2 buffer, 150 units of Dpn2.  After 
digestion, Dpn2 was inactivated at 65 C for 25 minutes.  The following components 
were added to the heat-inactivated material for second ligation at 15 C for 4 hours: 1.4 
	   54	  
mL 10X T4 ligase buffer, 12.6 mL cold nuclease-free water, 6000 units of NEB T4 
ligase.  The 4C material was ethanol precipitated and column purified using Zymo 
Research DNA concentrator kit.  150 uL 10 mM Tris-HCL (pH 8.0) was used to elute 
DNA. 
4C viewpoint primers were selected from human Nla3-Dpn2 primer pair database 
provided by Tayan’s group (http://compgenomics.weizmann.ac.il/tanay/?page_id=367).  
Primer pair sequences and illumina adapters are listed in table 4.  Sequential PCR 
using Expand Long Template Polymerase (Roche) was performed to construct 4C 
library.  Genomic primer pairs of 4C viewpoints were used for the first PCR, and the 
products were purified by Zymo Research DNA concentrator kit.  The PCR products 
were eluted in 10 mM Tris (pH 8.0) as the template for the second PCR using Illumina 
barcoded adapters as primers.  All PCR reactions were done in 8 replicates.  2 nM 4C 
library from each sample was pooled together before loading on the Illumina NextSeq 
500.  r3Cseq R package was used to analyze the data (93).  All sample were done in 
replicates. 
 
RNA isolation and qRT-PCR 
RNA was isolated using RNA Bee following the manufacture’s instructions.  1 ug of RNA 
was used for reverse transcription using BioRad iScript Advanced cDNA Synthesis Kit.  
30 ng of cDNA was loaded in a 20 uL qPCR reaction.  qPCR was performed using 
BioRAd CFX Touch Real-Time PCR Detection System.  Relative expression was 
calculated using delta delta Ct method. 
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Neural differentiation 
iPSC-derived 10 wk neurons were differentiated using monolayer protocol as described 
(70).  Briefly, 2-day post split iPSCs were switched to N2B27 medium supplemented 
with 500 ng/mL Noggin (R&D Systems) for 14 days with a complete change of medium 
every other day.  Colonies were split on to poly-ornithine and laminin-coated plates with 
1:2 ratio using StemPro EZ Passage tool (Life Technologies) for another week with a 
complete change of medium every other day.  These cells were trypsinized and replated 
to poly-ornithine and laminin-coated plates and supplemented with ROCKi overnight.  
Cells were kept in N2B27 for a few more days before switching to neural differentiation 
medium for a week.  These cells can be plated for terminally differentiated neurons at 
the density of 200,000 cells per well of a 6 well plate.  Cells were kept in neuron 
differentiation medium for another 5 week to obtain electrophysiological mature neurons 
for experiments. 
 
Results 
CTCF binds in an allele- and tissue-specific manner across the imprinted region 
of 15q11-13 
To test our previous speculation that CTCF at PWAR1 may be involved in 
stopping the distal portion of SNURF/SNRPN transcript, we examined allelic distribution 
of the binding by ChIP-seq using paternal-allele only AS-iPSCs and maternal-allele only 
PWS-iPSCs.  We found that CTCF preferentially binds to the paternal allele throughout 
	   56	  
the imprinted region from MKRN3 to UBE3A whereas the maternal counterpart did not 
show CTCF binding (Fig 1A).  Notably, the binding is bi-allelic outside the imprinted 
region (Fig 1A).  We confirmed the allele-specific CTCF binding by ChIP-qPCR on 3 
sites.  Two of them, SNRPN_U and PWAR1, are located within the imprinted region, 
and another, UBE3A_U, is located outside of the imprinted region.  CTCF binding is 
enriched at SNRPN_U and PWAR1 on the paternal allele, whereas UBE3A_U did not 
show allelic preference (Fig 1B).  Upon neural differentiation, CTCF binding was lost at 
PWAR1 and SNORD116 sites (Fig 1C) but not at SNRPN_U and UBE3A_U sites (Fig 
1D).  CTCF preferentially binds to the active paternal allele across the imprinted 
domain.  In neurons, reduced binding of CTCF at PWAR1, allows transcription to pass 
through and expresses the distal portion of SNURF/SNRPN transcripts.  Loss of CTCF 
binding at PWAR1 during neural differentiation supports our hypothesis that CTCF 
binding at PWAR1 is involved in stopping transcription in iPSCs and other non-neuronal 
cell types. 
 
CRISPR-mediated 24 kb deletion identifies the critical region regulating UBE3A-
ATS expression 
The region that separates the distal portion of SNURF/SNRPN lncRNA from the 
proximal portion of it is consist of a cluster of CTCF binding at PWAR1 as well as a 
stretch of weak poly-A sites at IPW (Fig. 2A).  RNA polymerase II (RNAPII) was shown 
to accumulate near CTCF binding sites at PWAR1 in human embryonic stem cells (H1-
ESC), suggesting that CTCF is blocking RNAPII from further transcribing.  RNA-seq 
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data from ENCODE showed that majority of RNA is terminated at IPW, and completely 
stopped at PWAR1 (Fig 2A).  Moreover, several atypical paternal deletions missing 
these two potential transcription termination signals showed the distal portion of 
SNURF/SNRPN transcripts including SNORD115 and SNORD109B.  As a result, we 
hypothesized that this 24 kb region containing poly-A signal and CTCF binding is critical 
for regulating the distal portion of SNURF/SNRPN, including SNORD115 and UBE3A-
ATS.  We deleted this region in AS iPSCs where there is only the active 
SNRUF/SNRPN allele.  Two separate approaches were used to generate the deletion in 
one experiment.  First, a pair of CRISPRs flanking IPW to PWAR1 was designed to 
make the deletion (ΔI-P).  Second, two single stranded oligonucleotides (ssODNs) were 
designed as homologous templates to insert loxP sequence at the cut sites.  All 4 
components were electroporated in AS iPSCs and 96 clones were screened.  We 
obtained 7 deletion clones and 1 clone with loxP inserted at both cut sites.  The loxP 
sites were recombined by Cre-recombinase to create the 24 kb deletion.  We picked two 
clones from CRISPR-mediated deletion and two clones from Cre-mediated deletion for 
data analysis.  Upon removal of the region, we detected the expression of SNORD115 
(Fig 1B), suggesting that this IPW to PWAR1 region is critical in controlling the distal 
portion of SNURF/SNRPN lncRNA. 
To rule out the possibility that the 24kb deletions disrupted transcription from the 
SNURF/SNRPN promoter, we examined the expression of SNRPN and SNORD116, 
two of the proximal portion of SNURF/SNRPN transcripts.  Our data also showed that 
SNRPN and SNORD116 remained the same across all deletion clones (Fig 2C), 
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suggesting that expression of SNORD115 is not due to up-regulation from the 
SNURF/SNRPN promoter. 
 
IPW and PAR1 comprise a bipartite transcriptional boundary 
To decipher individual functions of IPW and PWAR1, we deleted PWAR1 (ΔP) 
(~7kb) and IPW (ΔI) (~5kb) in AS iPSCs separately (Fig 3A).  In ΔP clones, we 
observed minimal expression of SNORD115 (Fig 3B).  In ΔI clones, the SNORD115 
expression was detected at 50% of SNORD115 expression levels seen in ΔI-P clones.  
This indicated that the two components work together to comprise the boundary 
function.  To rule out the possibility that sequences in between these two components 
may play a role in stopping transcription, we deleted IPW and PWAR1 sequentially, 
(ΔIΔP) leaving the sequence in between intact (Fig 2A).  The expression of SNORD115 
in ΔIΔP clones was almost identical to that in ΔI-P clones (Fig 2B).  This suggested that 
IPW and PWAR1 are the pivotal elements in stopping the distal portion of 
SNURF/SNRPN transcript. 
 
The boundary function of IPW and PWAR1 is directional 
Both CTCF-mediated looping function and poly-A signal-mediated transcriptional 
termination are known to be directional.  To test whether we can disrupt their function by 
inverting the sequence, we generated an IPW-PWAR1 inversion clone (INV) using the 
same pair of CRISPRs for ΔI-P (Fig 3A).  We did not detect SNORD115 expression in 
the inversion clone (Fig 3A), indicating the function of the inverted boundary is not 
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disrupted.  To dissect the individual role of the inverted IPW and PWAR1, we deleted 
them separately (Fig 3A) in an INV clone.  Although IPW was shown to be the more 
important component of the boundary component of the two, we did not detect any 
SNORD115 when the inverted IPW was deleted (INVΔI) (Fig 3B).  This suggested that 
the inverted IPW loses its function to stop transcription, perhaps due to the directionality 
of polyadenylation sequence.  Surprisingly, when the inverted PWAR1 region was 
deleted in the inversion line (INVΔP), SNORD115 was detected (Fig 3B), suggesting 
that the inverted PWAR1 has a gain-of-function property sufficient to stop transcription.  
Notably, SNORD115 expression in this line is about 40% of that in ΔI-P lines (Fig 3B), 
indicating the inverted IPW sequence may still function to interrupt transcription.  As a 
result, we sequentially deleted the inverted IPW in the INVΔP line (INVΔPΔI).  Although 
there was a slight increase in SNORD115 expression, it was not close to the level in ΔI-
P or ΔIΔP lines. 
To further demonstrate the directionality of IPW and PWAR1 in stopping 
transcription, we generated 2 additional inversions.  First, we flipped the inverted IPW 
back to its natural orientation in INVΔP line (INVΔP_INV-I) (Fig 3C).  This allowed us to 
demonstrate that IPW in the proper orientation works as a transcriptional block.  Indeed, 
SNORD115 in INVΔP_INV-I clone was dropped down to almost baseline, 
demonstrating the importance of its orientation (Fig 3D).  Second, we inverted PWAR1 
in ΔI line (ΔI_INV-P) (Fig 3E).  This allowed us take another approach to determine 
whether inverted PWAR1 had a gain-of-function.  SNORD115 in these clones showed 
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50% reduction compared to its parent line, suggesting that inverted PWAR1 has a gain-
of-function property (Fig 3F). 
 
Shortening the distance between SNURF/SNRPN promoter and UBE3A resulted 
in fully imprinting of UBE3A 
It is thought that UBE3A is imprinted when the distal portion of SNURF/SNRPN 
RNA that encompasses UBE3A-ATS is transcribed.  However, UBE3A imprinting was 
not observed in ΔI and ΔI-P clones where UBE3A-ATS is transcribed (Fig 4B).  We 
previously reported 80% imprinting of UBE3A in PWS iPSCs with an atypical deletion 
when the paternal SNURF/SNRPN promoter drives the expression of the distal portion 
of the transcript directly.  However, roughly 20% of cells showed some level of UBE3A 
expression by FISH and by strand-specific RT-PCR.  We speculated that cell division 
occurs before UBE3A is imprinted by UBE3A-ATS.  To address this question, we 
deleted the region from SNURF/SNRPN intron 1 to SNORD115-47 (ΔS-115) in AS 
iPSCs (Fig 4A).  This 303 kb deletion shared the same 5’ end of PWSSD, but with the 3’ 
end 110 kb close to UBE3A gene body.  This should eliminate the possibility that cell 
division takes place before imprinting of UBE3A.  Indeed, UBE3A is completely 
imprinted in these clones suggesting that shortening the distance between 
SNURF/SNRPN promoter to UBE3A affects the level of UBE3A imprinting (Fig 4C). 
 
Early imprinting of UBE3A occurs when the boundary is removed 
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We previously showed that UBE3A is imprinted in non-neurons when UBE3A-
ATS is transcribed.  Here, we showed that deletion of boundary element leads to 
expression of UBE3A-ATS transcript.  However, imprinting of UBE3A did not occur.  We 
hypothesized that imprinting of UBE3A requires higher level of UBE3A-ATS.  In 
addition, upstream exons of SNRPN have been hypothesized to drive SNURF/SNRPN 
lncRNA expression during neural differentiation, increasing the level of antisense 
transcripts.  Therefore, we differentiated the ΔI-P line along with the unmodified AS 
iPSC as control.  The time course showed that SNORD115 expression only increases in 
10wk neurons in the unmodified control whereas the expression from the ΔI-P line 
already exceeds it at 4wk and remains high afterwards (Fig 4D).  More importantly, 
UBE3A starts to show imprinting at 4wk and remained down at 10wk after neural 
differentiation (Fig 4E).  This suggested that higher level of transcription from the 
antisense direction is absolutely critical to silence UBE3A.  However, UBE3A is not 
completely abolished.  It is possible that the some of the UBE3A-ATS transcription 
machinery does not reach to UBE3A due to massive RNA processing in this region. 
 
Imprinting of UBE3A does not take place in the boundary-inverted neurons 
The inverted boundary in INV still functions as a boundary to stop transcription 
(Fig 3B). SNORD115 is expressed at a higher level at earlier time points compared to 
unmodified control (Fig 4D).  Interestingly, the SNORD115 expression remains about 
the same level at 10 wk whereas that of the unmodified control increases dramatically at 
10 wk (Fig 4D).  This suggests that although the inverted boundary loses its function to 
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entirely stop the transcription during earlier stages of neural differentiation, at later 
stages, the inverted boundary cannot be released.  Thus, imprinted expression of 
UBE3A is not seen in INV neurons.  This is most likely due to gain-of-function of the 
inverted PWAR1 because it reduced SNORD115 expression in the IPW deletion line 
when PWAR1 is inverted (Fig 3E). 
 
3D chromatin interaction does not change between iPSCs and neurons 
CTCF is a well-known chromatin architectural protein that creates stable 3D 
looping structure for chromosome integrity. CTCF ChIP-seq and ChIP-qPCR data 
showed that CTCF remains bound at two sites outside of the critical SNRPN-UBE3A 
imprinting region while majority of CTCF binding sites within this region were lost during 
differentiation, including the binding at PWAR1.  We hypothesized that SNRPN_U, 
PWAR1, and UBE3A_U forms a CTCF-mediated loop in iPSCs.  In neurons, PWAR1 is 
no longer attached to this loop allowing the transcript to pass through.  To test this 
hypothesis, we utilized circularized chromosome conformation capture followed by 
sequencing (4C-seq) to determine all the interactions loci with our viewpoints 
(SNRPN_U, UBE3A_U, and PWAR1).  Indeed, SNRPN_U and UBE3A_U showed very 
strong interactions in both iPSCs and neurons (Fig 5A).  PWAR1 is also part of this 
chromatin hub, but the interaction does not change between iPSCs and neurons as we 
hypothesized (Fig 5A).  Notably, PWAR1 interaction can only be detected when 
UBE3A_U is used as the viewpoint (Fig 5A).  It is not detected by SNRPN_U viewpoint, 
suggesting that there is steric hindrance between PWAR1 and SNRPN_U although they 
	   63	  
are in close proximity (Supplementary Fig 1).  Interestingly, PWAR1 seems to be very 
constrained in its own territory because most of its interactions are nearby 
(Supplementary Fig 2).  The aforementioned viewpoints did not show any interactions 
different between iPSCs and neurons, suggesting that this chromatin structure is very 
stable across different cell types (Fig 5A, Supplementary Fig 1,2). Thus, altered 
chromatin looping is unlikely to contribute to gene expression changes during 
neurogenesis. 
 
IPW showed subtle increase in interactions during neural differentiation 
When IPW is used as the viewpoint, the majority of interactions are locally with 
the exception of SNRPN_U in iPSCs (Supplementary Fig 3).  In neurons, the local 
interaction reduces and there are increase frequency of interactions around SNRPN and 
SNORD116 loci (Supplementary Fig 3).  These data suggest that a stable SNRPN-
UBE3A loop structure exists regardless of the cell type.  IPW and PWAR1 are spatially 
involved in this loop where IPW is in close proximity with SNRPN_U and PWAR1 is in 
close proximity with UBE3A_U.  During neural differentiation, IPW locus is no longer 
constrained allowing transcription machinery to continue transcribing the neuron-specific 
transcript. 
 
Discussion 
We use CRISPR/Cas9 to generate site-specific deletions to understand the 
mechanism by which UBE3A-ATS is regulated.  We show that UBE3A-ATS expression 
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is controlled by a bipartite boundary consisted of IPW and PWAR1 in iPSCs.  When the 
entire region is missing, the distal cluster of SNURF/SNRPN lncRNA is expressed 
including SNORD115 and UBE3A-ATS.  We further dissect the individual function of 
IPW and PWAR1.  We speculate that polyadenylation sites at IPW are the major 
transcription terminator.  When IPW is missing, transcription is not actively terminated 
and SNORD115 is detected.  However, the level of SNORD115 is only half compared to 
the deletion of entire IPW to PWAR1.  This suggests that PWAR1 interferes with 
transcription by blocking RNAPII when IPW loses its function.  Taken together, these 
two transcriptional boundary elements work together to block RNAPII from going further. 
We sought to disrupt the boundary by inverting the region.  To our surprise, the 
inverted sequence still functions as the boundary since no SNORD115 expression was 
detected.  We further dissected the function of the inverted IPW and PWAR1 
individually.  Deleting the inverted IPW did not disrupt the boundary function.  
Interestingly, deleting the inverted PWAR1 disrupted the boundary function as the 
SNORD115 expression was detected.  The inverted PWAR1 showed gain-of-function 
whereas the inverted IPW showed loss-of-function in terms of their ability to act as 
transcription terminators.  To further demonstrate the boundary function of IPW and 
PWAR1 is directional, we inverted IPW back to its natural sequence in the inverted cell 
line where PWAR1 is deleted.  SNORD115 expression was no longer detected.  We 
demonstrated the gain-of-function of PWAR1 by inverting PWAR1 in the cell line where 
IPW is deleted.  SNORD115 is significantly reduced.  It has been reported that the 
direction of CTCF binding determines the looping structure.  The inverted CTCF binding 
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at PWAR1 potentially gains new interactions and the interactions interfere with 
transcription.  To sum up, our data suggested that the transcriptional termination 
function of IPW and PWAR1 are directional. 
We previously reported that imprinting of UBE3A occurs in non-neuronal cells 
when UBE3A-ATS is actively transcribed.  However, imprinting of UBE3A was not 
observed in the boundary deleted cell lines where UBE3A-ATS is expressed.  We 
speculated that there is not enough transcription going through UBE3A gene body to 
imprint UBE3A.  We demonstrated that imprinting of UBE3A depends on the level of 
transcriptional events from the antisense direction in two ways.  First, we generated a 
paternal deletion that spans from SNURF/SNRPN intron 1 to SNORD115-45, 116 kb 
larger than the PWS SD to achieve complete imprinting of UBE3A.  UBE3A-ATS is 
transcribed strongly from the promoter without the massively processed SNORD116 
and SNORD115 regions.  UBE3A is completely imprinted in this 303 kb deletion line.  
Second, imprinting of UBE3A is achieved by differentiating the boundary-deleted iPSCs 
into neurons.  It is known that usage of the SNURF/SNRPN upstream exons occurs in 
neurons, and switches the expression from the coding portion of SNURF/SNRPN to the 
non-coding portion.  This increases the total amount of UBE3A-ATS transcription during 
neural differentiation.  Early imprinting of UBE3A was observed in the boundary-deleted 
neural progenitors, and the imprinting maintained in neurons. 
CTCF binding at chromosome 15q11-13 exhibits allele-specificity and tissue-
specificity.  CTCF binds to the paternal allele throughout the imprinted region.  The 
allele-specific binding does not present outside of the imprinted region.  Moreover, most 
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of the CTCF binding in the imprinted region is lost in neurons including the binding at 
PWAR1.  However, a few invariant sites showed no tissue-specificity.  The variant and 
invariant binding of CTCF between iPSCs and neurons led us to propose that CTCF 
mediates different chromatin structure between cell types.  Moreover, it has been 
reported that SNRPN to UBE3A region undergoes chromatin decondensation (94, 95).  
Our 4C data showed that a stable interaction exists between upstream of SNRPN and 
upstream of UBE3A.  PWAR1 is also involved in the hub.  This interaction, however, is 
not different between iPSCs and neurons.  Lost of CTCF at PWAR1 in neurons does not 
alter the interaction, suggesting that the participation of PWAR1 in the loop is probably 
CTCF independent. 
Altogether, we discovered minimal required regions that regulate UBE3A-ATS.  
They are comprised of IPW and PWAR1 that act together as a transcriptional terminator 
to stop transcription.  Both IPW and PWAR1 work in an orientation-specific manner, 
perhaps due to the mechanism by which transcription is terminated or interrupted.  We 
also demonstrated that upstream of SNRPN and UBE3A forms a stable interaction that 
is indifferent between cell types.  These findings provide essential information on how 
the UBE3A-ATS is regulated.  Several reports have focused on awakening the dormant 
UBE3A by blocking UBE3A-ATS as a treatment for AS.  Potential therapies can be 
developed by interfering with the transcriptional terminator to achieve the goal to 
reactivate the dormant UBE3A. 
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Figure 1.  Allele- and tissue-specific binding of CTCF at the 15q11-13 imprinted 
region.  A. A map of ChIP-seq tracks at subregion of chromosome 15q11-13.  Two 
biological replicates of AS iPSC CTCF tracks are shown in blue.  Two biological 
replicates of PWS iPSC CTCF tracks are shown in red.  B. ChIP-qPCR of three CTCF 
binding sites. PWAR1 and SNRPN_U are located within the imprinted region.  
UBE3A_U is located outside of the imprinted region.  C-D. CTCF binding during neural 
differentiation in AS. 
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Figure 2.  IPW to PWAR1 region serves as a boundary in regulating UBE3A-ATS.  
A. A map of IPW to PWAR1 region.  H1-hESC ChromHMM, H1-hESC RNAPII ChIP-seq 
track, Poly-A seq Brain track, h1-ESC RNA-seq track, and conservation track are 
shown.  Black lines denote the region deleted.  Red triangles denote LoxP sites.  B. 
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qRT-PCR of SNORD115 in the IPW-PWAR1 deletion lines.  C. qRT-PCR of SNRPN 
and SNORD116 in the IPW-PWAR1 deletion lines.  qRT-PCR was done in biological 
triplicates. 
 
	   70	  
 
Figure 3.  IPW and PWAR1 comprise the bipartite boundary and their functions 
are directional.  A,C,E. Schematic illustrations showing various deletion lines 
engineered.  Yellow color indicates 5’ and black color indicate 3’ of the original 
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orientation.  B,D,F. qRT-PCR of SNORD115 in various genome-engineered lines of 
IPW-PWAR1 region.  qRT-PCR were done in triplicates. 
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Figure 4.  Imprinting of UBE3A depends on the level of transcription from the 
antisense direction.  A. A map showing the size of the deletion in AS iPSCs.  B. qRT-
PCR of UBE3A-ATS comparing ΔI, ΔP, and ΔS-115.  C. qRT-PCR of UBE3A 
comparing ΔI, ΔP, and ΔS-115.  D. SNORD115 expression during neural differentiation.  
E. UBE3A expression during neural differentiation.  Blue lines denote control AS iPSC, 
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red lines denote inversion line, and green lines denote IPW-PWAR1 deletion line.  All 
qRT-PCR were done at least in biological triplicates. 
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Figure 5.  3D chromatin interactions at the imprinted region are largely 
unchanged between iPSC and neuron.  A. 4C-seq interactions of AS iPSC and 
neuron using UBE3A_U as the viewpoint.  Red dotted vertical line indicates the 
viewpoint.  Peaks indicate the interaction points with UBE3A_U.  Top box is the 
interaction in iPSC and the bottom box is the interaction in neuron.  Red and blue spider 
lines show the interactions with UBE3A_U viewpoints in iPSC and neuron, respectively. 
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Supplementary Fig 1.  Chromatin interactions between AS iPSCs and neurons 
using SNRPN_U as the viewpoint. 
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Supplementary Fig 2.  Chromatin interactions between AS iPSCs and neurons 
when PWAR1 is used as the viewpoint. 
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Supplementary Fig 3.  Chromatin interactions between AS iPSCs and neurons 
when IPW is used as the viewpoint. 
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Table 1. qPCR primers for ChIP 
Primer name sequence 
SNRPN_U_F GGTCTCTCAGTTGGCTCCTG 
SNRPN_U_R ATGGTGGATACTTGGCTTGG 
PAR1_F CAGGGAACGCTCTTCAACAT 
PAR1_R AACCAGTTCCAAACCTGACG 
UBE3A_U_F TGCTTCTGAACCCTGAATCC 
UBE3A_U_R CATGGACAAGTGTGTGTTGCT 
SNRPN_exon_F ATCTGTCTGAGGAGCGGTCAGT 
SNRPN_exon_R TCCCCAGGCTGTCTCTTGAG 
SNORD116_F GTTGGTGTTGCCTAGCATCC 
SNORD116_R CCTTGCAGGTCTTGGAAATC 
PAR1_mi_F CAGGGAAAGGGAGTTTGTTG 
PAR1_mi_R CGTGGGATTGTTTGATAGTGTG 
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Table 2. CRISPR sequences for genome manipulation 
CRISPR name sequence 
IPW 5’ #1 TATACAGAGCAATACGATCA 
IPW 5’ #2 GGAAAGGTTGGATTAAACTA 
IPW 5’ #4 TCTAAGAATTCCACTGGTGA 
IPW 3’ AACTAGCACATACAAGGAAC 
PAR1 5’ GTTCTGAAGCAAGGTATACC 
PAR1 3’ ATATAACCAAATTGTCCGTT 
SNRPN_intron 1 CAAGAACCTGGCATATACGA 
SNORD115-45 GACTCCATAGATTAACCCCC 
 
 
	   80	  
Table 3. PCR primers for clone-screening 
Primer name sequence 
IPW_T1 TTGCACATAAATATTGCCTTTCA 
IPW_T2 ACTGCCCTCCCTTTACCCTA 
IPW_T3 CTAGCCTTCCCCTTCCATCT 
IPW_T4 TGGGAGAATAAGAAGCGTTAAGA 
PAR1_T1 CCTCCCTCAAATTGCTCTTTT 
PAR1_T2 TTGTGCAAATGCAATATGTGA 
PAR1_T3 TCATATACGAGTTGAGTCCCAAT 
PAR1_T4 TGGTCTTTGGAAGGAGATGG 
PAR1_T4’ TGTTTTAATCTGCGTCCTTTTG 
SNRPN_intron_T1 GCTGAAAGACATTCGTTTGGA 
SNORD115-45_T4 CGCCACAATGGTGTCTTTTT 
IPW_F TCTTCTGCCTCCTGTCTCGT 
IPW_R TCCCATCACCACAGTGAAAA 
PAR1_F CAGGGAACGCTCTTCAACAT 
PAR1_R AACCAGTTCCAAACCTGACG 
PAR5_F AGGTGCTTTTGCTTTGCCTA 
PAR5_R TCTCTGAACCCCAACAGCTT 
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Table 4. 4C viewpoint primers for 4C-seq library preparation 
 
Genomic primer sequence 
SNRPN_U_NlaIII ACACTCTTTCCCTACACGACGCTCTTCCGATCTTCATAAGAAGTTGAAGCATG 
IPW_NlaIII ACACTCTTTCCCTACACGACGCTCTTCCGATCTGCTTTCTGGGAGAAGCCATG 
PWAR1_NlaIII ACACTCTTTCCCTACACGACGCTCTTCCGATCTATATGCCCACATTCCACATG 
UBE3A_U_NlaIII ACACTCTTTCCCTACACGACGCTCTTCCGATCTTTTGGATACCTTTCATCATG 
SNRPN_DpnII GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTCAGTTGGCTCCTGTATCATT 
IPW_DpnII GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTCCATAACCATCTAGTCCACAA 
PWAR1_DpnII GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTGCCCCAGGGAAAATAGTACC 
UBE3A_U_DpnII GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTTACTGTGGGTTTTTGGTTTT 
 
Table 5. Illumina HT adapter primers for 2nd PCR 
 
Illumina HT adapters  
Truseq_HT_D504 AATGATACGGCGACCACCGAGATCTACACGGCTCTGAACACTCTTTCCCTACACG
ACGCTCTTCCGATCT 
Truseq_HT_D505 AATGATACGGCGACCACCGAGATCTACACAGGCGAAGACACTCTTTCCCTACACG
ACGCTCTTCCGATCT 
Truseq_HT_D506 AATGATACGGCGACCACCGAGATCTACACTAATCTTAACACTCTTTCCCTACACGA
CGCTCTTCCGATCT 
Truseq_HT_D507 AATGATACGGCGACCACCGAGATCTACACCAGGACGTACACTCTTTCCCTACACG
ACGCTCTTCCGATCT 
Truseq_HT_D705_r
evcom 
CAAGCAGAAGACGGCATACGAGATTTCTGAATGTGACTGGAGTTCAGACGTGTGC
TCTTCCGATCT 
Truseq_HT_D706_r
evcom 
CAAGCAGAAGACGGCATACGAGATACGAATTCGTGACTGGAGTTCAGACGTGTG
CTCTTCCGATCT 
Truseq_HT_D707_r
evcom 
CAAGCAGAAGACGGCATACGAGATCTGAAGCTGTGACTGGAGTTCAGACGTGTG
CTCTTCCGATCT 
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4. Chapter 4 
Using AS iPSC-derived neurons as a tool to screen for drugs capable of 
unsilencing the dormant paternal UBE3A 
 
Data presented in this chapter are published in the following paper 
 
Title: Topoisomerases facilitate transcription of long genes linked to autism 
Authors: Ian F. King1, Chandri N. Yandava2, Angela M. Mabb1, Jack S. Hsiao3, Hsien-
Sung Huang1,7, Brandon L. Pearson1, J. Mauro Calabrese4, Joshua Starmer4, Joel S. 
Parker4,5, Terry Magnuson4,5, Stormy J. Chamberlain3, Benjamin D. Philpot1,2,6, and 
Mark J. Zylka1,2,6 
1Department of Cell Biology and Physiology, The University of North Carolina at Chapel 
Hill, Chapel Hill, North Carolina 27599, USA. 
2Carolina Institute for Developmental Disabilities, The University of North Carolina at 
Chapel Hill, Chapel Hill, North Carolina 27599, USA. 
3Department of Genetics and Developmental Biology, University of Connecticut Health 
Center, Farmington, Connecticut 06032, USA. 
4Department of Genetics, The University of North Carolina at Chapel Hill, Chapel Hill, 
North Carolina 27599, USA. 
5Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel 
Hill, Chapel Hill, North Carolina 27599, USA. 
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7Present address: Graduate Institute of Brain and Mind Sciences, College of Medicine, 
National Taiwan University, Taipei 10051, Taiwan. 
 
My contribution: Human iPSC-derived neurons to validate the findings in mouse neurons 
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Introduction 
Topoisomerase inhibitors can transcriptionally un-silence the paternal allele of 
Ube3a in mouse cortical neurons (26).  Ube3a is located adjacent to a cluster of 
imprinted genes, is normally expressed only from the maternal allele in neurons, and 
regulates synaptic function.  In humans, UBE3A is associated with two distinct 
neurodevelopmental disorders.  Specifically, deletion or mutation of maternal UBE3A 
causes Angelman syndrome, whereas duplication of the chromosomal region containing 
maternal UBE3A is frequently detected in individuals with autism (5).  Although 
topoisomerase inhibitors can un-silence the dormant allele of Ube3a in mouse, the 
effect of topoisomerase inhibitors need to be tested in human.  Here, we show that 
topoisomerase inhibitors downregulate UBE3A-ATS and unsilence the paternal UBE3A 
in human iPSC-derived neurons.  Similar to mouse neurons, the effect of topoisomerase 
inhibitors is on extremely long genes involved in synaptic functions.  In addition, many of 
these genes are listed as autism spectrum disorder (ASD) candidate genes. 
 
Materials and Methods 
iPSC culture and neuronal differentiation 
Human iPSC work was approved by the University of Connecticut Stem Cell Research 
Oversight Committee.  iPSCs that carry a large deletion of maternal 15q11-13 were 
cultured on irradiated mouse embryonic fibroblasts and manually passaged as 
described (10).  This cell line (AGdel1-0) was deemed exempt from IRB approval at the 
University of Connecticut due to its establishment in 1995 and lack of identifying 
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information.  iPSCs were differentiated into forebrain cortical neurons as described (10) 
with the following modifications: neural progenitors were generated by culturing iPSCs 
on feeders in N3B27 medium supplemented with noggin (500 ng/ml) for 8 days and then 
manually picking neural rosettes for two additional passages using trypsin and standard 
cell culture protocols.  Topotecan was applied to mature neurons and RNA was 
collected by standard protocols 6 days after the addition of drug of vehicle. 
 
qRT-PCR 
It was carried out as descried using Taqman (Life Technologies) gene expression 
assays for UBE3A (Hs00166580_m1) and UBE3A-ATS (Hs03454279_m1) according to 
the manufacturer’s instructions.  The Taqman assay for GAPDH was used as a control. 
 
RNA-seq 
Total RNA was collected as previously described (10).  Standard multiplexed mRNA 
libraries were prepared using Illumina kits.  Cluster generation and sequencing were 
performed using Illumina HiSeq 2000 platform.  Reads were aligned using Bowtie.  
Read counts were obtained using DEGseq, and normalization and analysis of 
differential gene expression was performed using the R package, edgeR, using a 
negative binomial model. 
 
Results 
Topotecan has the similar transcriptional effect on both mouse and human 
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Ube3a-ATS/UBE3A-ATS 
As founded previously, topotecan reduced the expression of an extreamly long (> 
1 megabase), paternally expressed antisense transcript that overlaps Ube3a (Ube3a-
ATS) (26).  The Ube3a-ATS is required for paternal Ube3a silencing (72, 96).  Notably, 
topotecan also reduced the expression of UBE3A-ATS and increased the expression of 
UBE3A in iPSC-derived neurons from an AS patient (Fig 1).  Topotecan thus had similar 
transcriptional effects at the Ube3a locus in mouse and human neurons. 
 
Topetecan reduces expression of long genes in neurons 
Because Ube3a-ATS is extremely long and was strongly downregulated, we 
hypothesized that topotecan might reduce the expression of other long genes.  RNA-
seq and Affymetrix microarrays data showed that topotecan reduced the expression of 
nearly all extremely long genes in mouse cortical neurons (Fig 2 A-C), with a strong 
correlation between gene length and reduced expression (for genes longer than 67 
kilobases (kb); Pearson’s correlation coefficient (R) = -0.69).  Topotecan also reduced 
the expression of long genes in iPSC-derived human neurons (Fig 2D).  Specifically, the 
percentage of genes that were inhibited (to any extent) by 300 mM topotecan increased 
from 50% for genes 67 kb in length to nearly 100% for genes ~200 kb and longer.  In 
addition, inhibition of long genes by topotecan was highly dose dependent (Fig 3). 
 
Numerous Autism Spectrum Disorder (ASD) genes are affected 
To investigate further the biological consequences of topotecan treatment in 
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neurons, we defined a list of genes that were differentially expressed with high 
confidence.  From RNA-seq expression data, we found that topotecan significantly 
downregulated 155 genes and significantly upregulated 28 genes.  The topotecan-
downregulated genes were significantly longer than all expressed genes in cortical 
neurons, further suggested that topotecan has pronounced effects on long genes.  On 
the basis of Gene Ontology and functional annotation terms, we found that many 
topotecan-downregualted gene were involved in neuronal development and synaptic 
function.  Because ASD is thought to be a neurodevelopmental disorder that affects 
synapses, we cross-referenced out list of downregulated genes with know ASD 
candidate genes, combining genes in the SAFRI Gene database with candidates 
identified in recent exome sequencing studies (97–101).  27% of the 183 differentially 
expressed genes are known ASD candidate genes (Table 1), a proportion that is highly 
significant compared to chance. 
 
Discussion 
We show AS iPSC-derived neurons can be a great tool to screen for compounds 
that unsilence the dormant UBE3A.  The finding also suggested that the underlying 
mechanism by which Ube3a-ATS/UBE3A-ATS silences Ube3a/UBE3A are very similar 
between mouse and human neurons.  It is striking that topoisomerase inhibitors affects 
extremely long genes, and many of those genes are listed as ASD genes.  
Topoisomerase was the first compound shown to reactive the silent Ube3a/UBE3A (26).  
However, its application of being a therapy for AS requires more intensive studies as it 
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affected so many other genes involved in synaptic functions in the brain.  A recent study 
using antisense oligo to specific downregulate Ube3a-ATS in mouse neuron 
demonstrated more potential as a therapy (27).  Nonetheless, it needs to be tested in 
human neurons to show its efficacy to unsilence the dormant paternal allele. 
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Figure 1. Topotecan reduces UBE3A-ATS and reactivates UBE3A expression in 
AS iPSC-derived neurons. Expression of UBE3A and UBE3A-ATS in iPSC-derived 
neurons from an Angelman syndrome patient carrying a maternal deletion of the 15q11-
13 region. Differentiated neuronal cultures were treated with 10 nM-10 uM topotecan or 
vehicle for 6 days. Expression quantified by qPCR. **P < 0.01, one-way analysis of 
variance with Dunnet’s post-hoc test. n = 4. Error bars represent s.e.m. 
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Figure 2. Topotecan reduces expression of long genes in neurons. A. Mouse 
cortical neurons treated with vehicle (v) or 300 nM topotecan (drug; d) for 3 days (n = 5 
biological replicates). RNA-seq gene expression versus gene length. B. Mean 
expression change in bins of 200 genes by length. C. Percentage of genes that were 
reduced in expression by topotecan; plotted as a sliding window of 100 genes by length, 
RNA-seq data (log scale). Inset, same data on linear scale. D. iPSC-derived human 
neurons treated with 1 uM topotecan for 6 days relative to vehicle, RNA-seq data in bins 
of 200 genes by length (n = 2 biological replicates). 
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Figure 3. Topotecan dose-response.  Mouse cortical neurons were treated with 3 nM, 
30 nM, 150 nM, 300 nM and 1000 nM topotecan for 3 days (n=3 for 300 nM topotecan, 
all other doses n=1).  Gene expression was analyzed by Affymetrix microarrays, plotted 
as mean expression change in bins of 200 genes. 
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Table 1. Topotecan reduces expression of numerous ASD candidate genes in 
neurons 
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5. Chapter 5  
Significance and Future directions 
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The discovery of iPSC as a model to study human diseases has a fundamental 
impact on biological research.  Specifically, it has re-shaped the research on human 
neurological disorders.  With the previously developed neural differentiation protocols 
from stem cells, understanding neurogenetic disorders during development has never 
been easier.  Researchers can acquire somatic cells from individuals with disorders and 
reprogram the cells into iPSCs for neural differentiation to study the differences between 
normal and disease states.  Numerous reports of disease-modeling using iPSCs have 
been published, including our diseases of interest.  The recent discovery of 
CRISPR/Cas9 in which genome can be manipulated in a site-specific manner changes 
the field of biological research once more.  This technology has brought so much 
potential not only to basic research, but also to genetic medicine.  We took advantage of 
both technologies and applied it to understand the regulation of UBE3A-ATS and 
imprinting of UBE3A in the context of AS. 
My main research goal focused on identifing the mechanism by which UBE3A-
ATS is regulated.  Understanding the regulation of UBE3A-ATS allows us to intervene 
its process as a new approach to unsilence the paternal UBE3A.  We first noticed a 
PWS patient who has a very unique deletion paternally-inherited allele.  We acquired 
fibroblasts from this individual and reprogramed to iPSCs.  Our data agreed with the 
reported article that neuron-specific UBE3A-ATS is expressed in non-neurons.  We 
further discovered that imprinting of UBE3A does not require any neuronal factors and 
hypothesized that a region encompasses a stretch of polyadenlyation sequences as 
well as a cluster of CTCF binding sites is the key to UBE3A-ATS regulation.  In order to 
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prove our hypothesis, we utilized CRISPR/Cas9 to delete regions in AS iPSCs where 
paternally-inherited allele is the only allele present.  After examining the SNORD115 
expression in many deletion lines, we discovered that ~5kb region of IPW that contains 
polyadenylation sites and ~7kb region of PWAR1 that contains a cluster of CTCF 
binding sites are absolutely essential to control the UBE3A-ATS expression. 
We also discovered that the imprinting process of UBE3A during neuronal 
differentiation is disrupted when the critical region is inverted.  Although UBE3A-ATS is 
transcribed in the boundary inverted cell line, its level is not sufficient to imprint UBE3A.  
Furthermore, we discovered that imprinting of UBE3A is dependent on the level of 
UBE3A-ATS transcribed.  We do not know if the transcribed RNA that is essential to 
silence UBE3A, or the active transcribing RNAPII going through UBE3A gene body that 
is required to silence UBE3A.  More experiments need to be done to unravel the 
mechanism.  GRO-seq, a nuclear run-on assay that determines the location of a 
transcribing RNAPII at a certain time point, is the technique useful to identify where the 
UBE3A-ATS and UBE3A collide.  We generated a cell line with the expression of 
UBE3A-ATS but no imprinting of UBE3A.  We also generated a cell line with the 
expression of UBE3A-ATS and imprinting of UBE3A.  These two cell lines are useful for 
studying where RNAPII collides. 
The tissue-specific CTCF binding at PWAR1 led us to hypothesize that CTCF acts 
as a boundary in non-neurons to stop transcription, whereas in neurons, the binding is 
lost allowing transcription to continue and imprints UBE3A.  However, deletion of 
PWAR1 in AS iPSC did not support this hypothesis.  We did not observe any 
	   95	  
reactivation of SNORD115 nor UBE3A-ATS in these engineered cell lines.  The binding 
of CTCF occurs throughout the paternal allele of the chromosome 15q11-13.  The 
tissue-specific binding pattern of CTCF is also observed on many of the binding sites.  
This binding pattern between iPSCs and neurons led us to re-hypothesize that there are 
tissue-specific differences of CTCF-mediated looping structure during neural 
differentiation.  The change in looping structure contributes to the neuron-specific 
UBE3A-ATS expression.  Indeed, we identified a looping structure at the imprinted 
SNRPN to UBE3A region.  PWAR1 is also involved in this loop.  However, the loop 
structure does not change during neural differentiation.  This indicates that regulation of 
UBE3A-ATS does not result from changes in chromatin structure.  Nonetheless, 
PWAR1 region in clearly involved in participating transcription interference.  When 
PWAR1 region is present in the IPW deleted line, UBE3A-ATS level is only half of that 
in the IPW and PWAR1 deleted line.  When PWAR1 region is inverted, it alone is able to 
stop the transcript.  It is possible that proteins other than CTCF bound at PWAR1 region 
are involved in the transcription termination process. 
In summary, iPSC is a great tool for disease modeling and drug screening as 
described in various chapters.  In combination with the CRISPR/Cas9 gemone-editing 
tool, we have made a huge break through in terms of UBE3A-ATS regulation as well as 
UBE3A imprinting.  We showed that genomic region of IPW and PWAR1 are essential 
for UBE3A-ATS regulation, and their transcriptional termination functions are directional.  
However, more experiments need to be done to decipher what the essential element(s) 
is/are in the process of stopping transcription within IPW and PWAR1 region.  In 
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addition, imprinting of UBE3A is not a simple process by having its reciprocal UBE3A-
ATS.  Imprinting either requires a substantial amount of UBE3A-ATS transcribed, or the 
substantial transcription units from the antisense direction colliding with that from the 
sense direction.  Although we have achieved identifying the fundamental components 
that regulate UBE3A-ATS, there remain many questions to be answered.  Continuing 
this research will give hopes to the AS individual and their families that one day, we will 
develop therapies to help them improve their life. 
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